Embed Size (px)
Citation preview
Page 1 of 26
CURRICULUM VITAE
Name: Harry (G.M.M.) Bartelink
Address: Scheepmakersdam 20, Warmond, The Netherlands
Date/Place of birth: 20 May l946, Oldenzaal, The Netherlands
Family: Married, 4 children
Degrees: 1970: MSc University of Nijmegen
1973: M.D. University of Nijmegen
1980: Ph.D. University of Amsterdam
Thesis: 1980: Lymphnode metastases of squamous all carcinoma in
the head and neck region: the role of radiotherapy
Present appointments:
1) Radiation Oncologist The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam
2) Professor in Clinical Experimental Radiotherapy of the University of Amsterdam
Previous appointments:
1) Chairman Radiotherapy Department, The Netherlands Cancer Institute-Antoni van Leeuwenhoek,
Amsterdam (1985-2007)
2) Consultant in Radiotherapy:
- St. Lucas Hospital, Amsterdam
- Kennemer Gasthuis, Haarlem
3) Consultant Institut Gustave Roussy Paris
4) Professeur Associé à l'Université Paris-Sud.
Clinical training and positions:
1973-1977: Resident: Radiotherapy Department, The Netherlands Cancer Institute-Antoni van
Leeuwenhoek Ziekenhuis, Amsterdam (Under leadership of the late Prof. K. Breur)
1978: Radiation oncologist, The Netherlands Cancer Institute-Antoni van Leeuwenhoek
Ziekenhuis, Amsterdam
1973: Radiology Department, University Hospital, Nijmegen
Chairman: Prof. W. Penn
1974: Radiotherapy Department, Wilhelmina Hospital, University Amsterdam
1976: Rotterdam Radiotherapeutic Institute
Chairman: Prof. B. v.d. Werf-Messing
1977: Mayo Clinics, Rochester, Minnesota, U.S.A.
Chairman: Prof. J. Earle
1978: Institute Gustave Roussy, Paris
Chairman: Prof. M. Tubiana
1982: Stanford University, Palo Alto, U.S.A.
- Radiobiology Department, Chairman: Prof. R.F. Kallman
- Radiotherapy Department, Chairman: Prof. M. Bagshaw
1985: Visiting professor, Stanford
University Radiobiology Department, Palo Alto, U.S.A.
2008-2011 Consultant Institut Gustave Roussy Paris and Professeur Associé à l'Université
Paris-Sud.
Page 2 of 26
Awards:
- Honorary Member of the Schweizerische Gesellschaft für Medizinische Radiologie (SGMR)
(Switzerland, 1991)
- ASTRO: Special keynote address award (annual meeting 1993)
- Honorary Fellow of the American College of Radiology (1997)
- Breur Medallist (ESTRO, 1997)
- M. Burger-award (Cairo, Egypt, 1998)
- G.H. Fletcher Award (ICTRO 2000, Lugano, 2000)
- Honorary Member of the Societas Oncologicorum Radiotherapeutic Corum Polonorum (2004)
- Morton M. Kligerman Award (University of Pennsylvania Philadephia, USA, 2004)
- Antoine Béclère Award (Paris; France, 2005)
- Kilroe Award, Section of Coloproctology (Royal Society of Medicine, Manchester 2006)
- Regaud medal (ESTRO, Leipzig, 2006)
- “Ridder in de Orde van de Nederlandse Leeuw” by the Queen of the Netherlands (2007)
- J. Franz Buschke Award (SFRO, ICRR, San Francisco, 2007)
- Janeway Gold medal Award (American Radium Society, Amsterdam, 2007)
- Doctora Honoris Causa (University of Gdansk, 2008)
- The European Breast Cancer Science Award (Glasgow 2014)
- The ESTRO Lifetime Achievement Award (2015)
- The ECCO Lifetime Achievement Award (2015)
Clinical activities:
As chairman responsible for patient care and scientific research at the Radiotherapy Department (total
staff: 300) with particular interest in clinical experimental research. 4300 patients are treated
in this department per year.
The scientific activities in the past concerned the interaction of radiotherapy and chemotherapy in patients
with lung, breast and head and neck cancer. At present predictive assays indicating adaptation of
treatment schedules and image guided intensity modulated radiotherapy are subjects of interest
Research:
As chairman of the Radiotherapy Department responsible for the research activities in the following
divisions:
1) Radiotherapy Department
2) Experimental Radiotherapy Department
3) Physics and Engineering Department
External research funds 1985 - 2014:
1) NKB/NKI 84-1 project: A study of the radiosensitizing effects of cisplatin and related drugs on
tumors and normal tissues in mice
2) NKB/NKI 85-2 project: Residual damage in slowly dividing tissues after irradiation or
chemotherapy and the consequences for retreatment
3) NKB/NKI 88-2 project: Intratumoral injections ofslow drug release systems with radiosensitizers
and cytostatic drugs to improve the efficacy of radiotherapy
4) A1024: Commission of the European Communities (CEC): AIM-project: Real time imaging and
quality control in radiation therapy. (pilot phase AIM.)
5) NKB/NKI 91-01 project: High-precision radiation therapy with on-line treatment set-up verification
6) ABMH1 CT921615: Commission of the European Communities (CEC): DGXII Biomed 1:
Assessment of the impact of improved local control by radiotherapy on survival in cancer patients.
Page 3 of 26
(CIPD 930115 / 940205)
7) NKB/NKI 92-47 project: Prediction of radiosensitivity and repopulation rates in human tumors
8) NKB/NKI project: Prediction of radiotherapy response using FISH to assess chromosome damage
in tumors and normal tissues
9) NKB/NKI project: Functional activity of the estrogen receptor in human breast cancer
10) EC-project 1996: Clinical Oncology Network for Quality in European Standards of Treatment
(CONQUEST) (DGXIII: HC1009)
11) NKB/NKI project: The role of the sphingomyelin signal transduction pathway in radiation-induced
apoptosis
12) Dutch Cancer Society grant (1998)
Clinical implementation of conformal radiotherapy of lung cancer using dynamic intensity
modulation
13) Dutch Cancer Society grant (1998)
Genetic alterations involved in local recurrence and progression of invasive and non-invasive
breast cancer after breast conserving therapy
14) NKB/NKI 99-2035 project: Quantitative assessment of treatment margins and implementation of
multimodality imaging in breast-conserving therapy
15) NKB/NKI 02-2655: Local recurrence, distant metastasis and death in young breast cancer
patients: clinical, histological and micro-array analysis
16) NKI 2001-2357
Micro-array analysis of breast cancer as a diagnostic tool to guide optimal treatment
17) NKB/NKI 2005-3373
Radiation-induced atherosclerosis: mechanisms and preventive Intervention strategies.
18) NKI 2004-30
Application of Pathology-correlated Imaging to Improve the accuracy of Surgery and
Radiotherapy in Breast-conserving therapy
19) NKI 2009-4389 Preoperative accelerated partial breast irradiation (PAPBI): defining radiotherapy
sensitivity
20) EU 257144 ARTFORCE: Adaptive and innovative Radiation Treatment FOR improving Cancer
patients treatment outcome (2012)
PROMOTOR (graduations PhD):
1) 1986: Co-promotor of L. Dewit
Thesis: Tolerance of the small and large intestine to irradiation and cis-diaminedichloroplatinum II
2) 1989: Co-promotor of ir. H. Meertens
Thesis 'cum laude': On-line acquisition and analysis of portal images
3) 1991: Promotor of C. Koning
Thesis: Radiotherapy and cisplatin: a perspective -From retrospective to prospective studies in
patients with non-small cell lung cancer-
4) 1992: Promotor of M. van Herk
Thesis 'cum laude': An electronic portal imaging device. Physics, development and application
5) 1992: Promotor of J. Bijhold
Thesis: Evaluation of treatment setup in radiotherapy using an electronic portal imaging device
6) 1993: Promotor of F. Wittkämper
Thesis: Absorbed dose determination in radiotherapy (Uniformity and uncertainties under
reference and clinical conditions)
7) 1995: Promotor of M.F.M. Smeets
Thesis: Factors affecting human tumor cell radiosensitivity: molecular studies
8) 1995: Promotor of L.J. Boersma
Thesis: Lung function and radiotherapy; An analysis of local and overall radiation effects
Page 4 of 26
9) 1995: Promotor of S. Heukelom
Thesis: Quality Assurance in Radiotherapy: an in-vivo dosimetric study of the accuracy in dose
calculation and dose delivery
10) 1995: Promotor of J.H. Borger
Thesis: Breast conserving therapy. Predictive factors for treatment outcome
11) 1995: Promotor of K.G.A. Gilhuijs
Thesis 'cum laude': Automated verification of radiation treatment geometry. Reconstruction of
patient setup in two and three dimensions using portal images
12) 1996: Promotor of A. Bel
Thesis: Conformal therapy: hitting a moving target
13) 1996: Promotor of M. Essers
Thesis: In Vivo Dosimetry In Radiotherapy. Development, use and evaluation of accurate patient
dose verification methods
14) 1996: Promotor of M. Verheij
Thesis ‘cum laude': Radiation injury of the kidney. Mechanisms and Modulation of Endothelial Cell
Dysfunction
15) 1997: Promotor of G. van Tienhoven
Thesis: Quality assurance apex biopsy and local control in Breast Cancer
16) 1977: Promotor of C.P.J. Raaijmakers
Thesis: Dosimetry and treatment planning for Boron Neutron Capture Therapy
17) 1998: Co-promotor of I.M. Verdonck-de Leeuw
Thesis: Voice characteristics following radiotherapy: the development of a protocol
18) 1998: Promotor of R. Boellaard
Thesis: In vivo dosimetry with a liquid-filled electronic portal imaging device
19) 1998: Promotor of H.W.P.M. Kemperman
Thesis: Breast Conserving Therapy; Experience at the Netherlands Cancer Institute, with
special interest for the problem of local recurrence
20) 1998: Promotor of A.C. Voogd
Thesis: Breast-conserving treatment of operable mammary cancer: evaluation of patient
selection and treatment outcome. (studies based on regional, national and European data)
21) 1999: Promotor of P.J.M. van der Vaart
Interaction of platinum coordination compounds with radiation of hyperthermia: from laboratory to
clinic
22) 1999: Promotor of L. Moonen
Radiotherapy in bladder cancer: selection of patients and optimization of treatment
23) 1999: Promotor of J. Theuws
Pulmonary effects of radiotherapy. A clinical analysis
24) 1999: Promotor of F.A. Pameijer
Pre- and post-radiotherapy computed tomography in laryngeal and hypopharyngeal cancer:
Imaging-based prediction of local control
25) 2000: Promotor of N.S. Russell
Individual variation in normal tissue reactions to radiotherapy: correlations with radiobiological
parameters
26) 2001: Promotor of M.A.J. van Dijk
Functional activity of human estrogen receptor alpha in normal human breast tissue and breast
cancer
27) 2001: Promotor of C. Vrieling
First analyses of the EORTC "boost versus no boost" trial with an emphasis on cosmesis. The
beauty of the breast
28) 2001: Promotor of C. Rasch
Observer and imaging variation in conformal radiotherapy
Page 5 of 26
29) 2001: Promotor of C. Hurkmans
Improvement of breast cancer irradiation techniques
30) 2002: Promotor of M. Engelsman
Designing IMRT for lung cancer
31) 2002: Promotor of Y. Seppenwoolde
Radiation induced lung damage
32) 2002: Promotor of M.R. Chrisitaens
Documentation, a tool for quality assessment in breast cancer surgery
33) 2003: Promotor of G.A. Ruiter
Effects of anticancer Alkyl-lysophospholipids on cell death and survival
34) 2003: Promotor of L.S. Ploeger
Image-based verification of patient setup and treatment geometry in radiotherapy
35) 2004: Promotor of B.C.J. Cho
Improving radiotherapy treatment for left sided breast cancer
36) 2004: Promotor of G.J. Meijer
Clinical implementation of high precision radiotherapy for urogenitical tumours
37) 2005: Promotor of E.E. Deurloo
Correlation of diagnostic breast imaging data and pathology: application to diagnosis and
treatment
38) 2005: Promotor of K. de Jaeger
Radiation-induced pulmonary toxicity in non-small cell lung cancer
39) 2006: Promotor of F.J. Pos
Brachytherapy and external beam radiotherapy in muscle invasive bladder cancer
40) 2006: Promotor of R.L.M. Haas
Low dose radiotherapy in indolent lymphomas, enough is enough
41) 2007: Promotor of R.J.H.M. Steenbakkers
Optimizing target definition for radiotherapy
42) 2007: Promotor of B.M.P. Aleman
Optimizing treatment of patients with Hodgkin’s lymphoma
43) 2007: Promotor W.F.A. Klein Zeggelink
Quantative evaluation of uncertainty in the radiological assessment of breast tumor extent:
effect on treatment
44) 2007: Promotor of J.S.A. Belderbos
Radiotherapy in lung cancer “a moving field”
45) 2007: Promotor of M. Schwarz
Intensity-modulated radiotherapy techniques for prostate, head-and-neck and lung cancer
46) 2007: Promotor of Ph. Meijnen
Changing patterns in diagnosis in the treatment of ductal carcinoma in situ of the breast and
related clinical outcomes
47) 2007: Promotor of S.T.H. Peeters
High dose radiotherapy in prostate cancer: results of the Dutch multicenter randomized phase
III trial
48) 2007:Promotor of F.J.P. Hoebers
Prognostic factors and predictive tests in the treatment of head and neck squamous cell
Carcinoma
49) 2009: Promotor of E.P.M. Jansen
Chemoradiotherapy in Gastric Cancer
50) 2010: Promotor of D. Nuyten
Hypothesis driven gene expression profiling in breast cancer
51) 2011: Promotor of B. Kreike
Gene expression profiling of breast cancer to identify subtypes and to predict local recurrence
Page 6 of 26
after breast conserving therapy
Present functions:
1) Member of European Academy of Cancer Sciences
2) Member of Advisory board INCa
3) Member supervisory board Maastro Clinic
4) Supervisory board member Agendia N.V.
Previous functions:
1) Chairman scientific committee of the ESTRO conference - Lisbon, Portugal (1986)
2) Organizer/chairman of the Brachytherapy Working Conference, The Hague, The Netherlands
(1988)
3) Director ESTRO-ESMO teaching course on early breast cancer, London, England (1989)
4) Member of the EORTC Protocol Review Committee (1983-1989)
5) Chairman scientific committee: ESTRO conference -Montecatini, Italy (1990)
6) Co-organizer of the Asilomar Congress, Montery, USA (1990)
7) Member of the Scientific Committee of the ECCO-6 conference, Florence, Italy (1991)
8) Chairman and co-editor of the Consensus Meeting (on quality control in treatment of early breast
cancer) of the EORTC Radiotherapy Cooperative Group, Tubingen, Germany (1991)
9) Chairman and co-editor of the Consensus Meeting (on high dose high precision in radiotherapy) of
the EORTC Radiotherapy Cooperative Group, Geneva, Switzerland, (1993)
10) Chairman of the EORTC Breast Cancer Working Conference, Amsterdam, The Netherlands
(1994)
11) Chairman of Scientific Board of ECCO-8 conference, Paris, France (1995)
12) Chairman/organizer of the Prostate Cancer Symposium; new developments in the management of
prostate cancer, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Huis, Amsterdam,
The Netherlands (February 1996)
13) Chairman of the EORTC Radiotherapy Cooperative Group (1991-1996)
14) Editor-in-chief of the journal Radiotherapy and Oncology (1991-1996)
15) Secretary General of the International Society for Radiation Oncology (ISRO)
16) Chairman of the Scientific Board of the European Cancer Center
17) Member of the Medical Advisory Board of the Comprehensive Cancer Center Amsterdam (IKA)
18) Coordinator CONQUEST-project (EC telematics Frame work)
19) Member of the Scientific Board of the Dutch Cancer Foundation
20) Treasurer of FECS
21) Chairman scientific committee of the ESTRO conference, Lisbon, Portugal (2001)
22) Member of the Scientific Audit Committee of the EORTC
23) Professor in Clinical Experimental Radiotherapy of the Free University Amsterdam
24) Editorial board member Nederlands Tijdschrift voor Geneeskunde (NTvG)
25) Member of the Editorial Advisory Board of the International Journal The Breast
26) Board member of Editorial Consultants of the European Journal of Cancer
27) Editorial board member of the International Journal of Radiation, Oncology, Biology and Physics
28) Past-president of ESTRO since September 2003
29) Past-President of FECS since November 2005
30) Member of the Editorial Advisory Board of the international journal Cancer Treatment Reviews
31) Member of the Editorial Board of The Cancer Journal from Scientific American
32) Member of the Editorial Board of the journal The Oncologist
33) Member of the Executive Committee Eusoma
34) Member of the Consultant of the International Relations Committee of the ASTRO
35) Editorial board member of Cancer Letters
36) Editorial board member of Seminars in Radiation Oncology
Page 7 of 26
37) Editorial board member of Journal “Reports of Practical Oncology and Radiotherapy” (Poland)
38) Cancer Trials Advisory and Awards Committee (CTAAC)
39) Member of ASTRO leadership team
40) Member of international affairs committee meeting of Amecrican Society of Clinical Oncology
41) Member of Faculty of 1000 Medicine
42) Member of Editorial Advisory Board the Journal of Cancer Surgery
Active member of:
1) EORTC Breast Cancer Cooperative Group
2) EORTC Radiotherapy Cooperative Group
3) Multi University Breast Oncology Group
4) American Society for Therapeutic Radiology and
Oncology (ASTRO)
5) American Society of Clinical Oncology (ASCO)
6) European Society of Mastology (EUSOMA)
7) European Society for Medical Oncology (ESMO)
Explanation of abbreviations:
AIM: Advanced Informatics in Medicine
ASTRO: American Society for Therapeutic Radiology and Oncology
ESTRO: European Society for Therapeutic Radiology and Oncology
ESMO : European Society of Medical Oncology
EORTC: European Organization for Research and Treatment of Cancer
Eusoma: European Society of Mastology
FECS: Federation of European Cancer Societies
ICTRO: International Conference on Translational Research and Pre-Clinical Strategies in Radio-
Oncology
NTvG: Nederlands Tijdschrift voor Geneeskunde (NTvG): Dutch Journal for Medicine
Publications
A) Articles in international peer reviewed scientific journals
1. Bartelink H, Battermann J, Hart G. Half body irradiation. Int J Radiat Oncol Biol Phys
1980;6;1:87-90
2. Bartelink H, Breur K, Hart G. Radiotherapy of lymph node metastases in patients with
squamous cell carcinoma of the head and neck region. Int J Radiat Oncol Biol Phys 1982;8;6:
983-989
3. Bartelink H, Snow GB, Annyas AA, van Slooten EA, Hart AAM. Prognostic factors for neck
node metastasis. Clin Otolaryngol 1982;7:185-192
4. Bartelink H. The effects of Cisplatin on tumour, skin and gut in mice. Int J Radiat Biol
1983:43;6: 695-696
5. Bartelink H, Breur K, Hart G, Annyas B, Van Slooten E, Snow G. The value of postoperative
radiotherapy as an adjuvant to radical neck dissection. Cancer 1983;52(6):1008-1013
6. Bartelink H. Prognostic value of the regression rate of neck node metastases during
radiotherapy Int J Radiat Oncol Biol Phys 1983;9:993-996
7. Hayward JL, Bartelink H. Breast conserving therapy in operable breast cancer; workshop
report Eur J Canc Clin Oncol 1983;19(12):1749-1751
8. Dewit L, Bartelink H, Rumke Ph. Concurrent cis diamminedichloroplatinum (II) and radiation
treatment for melanoma metastases: a pilot study. Radiother Oncol 1985;3:303-309
9. Dewit L, Oussoren Y, Bartelink H, Stewart F. Differences in the acute intestinal syndrome after
partial and total abdominal irradiation in mice. Int J Radiat Biol 1985;48:745-752
10. Dewit L, Begg AC, Koehler Y, Stewart FA, Bartelink H. Influence of
cisdiamminechloroplatinum on mouse duodenal crypt stem cell survival after multifraction X-
Page 8 of 26
ray treatment. Int J Radiat Oncol Biol Phys 1985;11:1809-1816
11. Dewit L, Oussoren Y, Bartelink H. Dose and time effects of cis-diamminedichloroplatinum(II)
and radiation on mouse duodenal crypts. Radiother Oncol 1985;4:363-371
12. Bartelink H, Van Dam F, Van Dongen J. Psychological effects of breast conserving therapy in
comparison with radical mastectomy. Int J Radiat Oncol Biol Phys 1985;11:381-385
13. Lebesque J, Blank L, Bartelink H, Van der Laarse R. Field matching in breast irradiation: an
exact solution to a geometrical problem. Radiother Oncol 1986;5:47-57
14. Dewit L, Oussoren Y, Bartelink H. The effects of Cis diamminedichloroplatinum(II) and
radiation on the proliferation kinetics of mouse duodenal crypt cells and on a partially
synchronized crypt cell population. Int J Radiat Oncol Biol Phys 1986;12:1977-1985
15. Dewit L, Oussoren Y, Bartelink H. The relationship between proliferation rate and the effects
of Cis-platinum and X-rays on mouse duodenal crypt cells. Br J Cancer 1986;53 (sVII):33-36
16. Keus R, Bartelink H. The role of radiotherapy in the treatment of desmoid tumors. Radiother
Oncol 1986;7:1-5
17. Stewart FA, Bohlken S, Begg A, Bartelink H. Renal damage in mice after combined treatment
with cisplatinum alone or in combination with X-irradiation. Int J Radiat Oncol Biol Phys
1986;12:927-933
18. Bartelink H, Kallman RF, Rapacchietta D, Hart AAM. Therapeutic enhancement in mice by
clinically relevant dose and fractionation schedules of c DDP and irradiation. Radiother Oncol
1986;6:61-74
19. Schaake Koning C, Bartelink H, Hora Adema B, Schuster Uitterhoeve L, Van Zandwijk N
Radiotherapy and cis diamminedichloroplatinum(II) as a combined treatment modality for
inoperable non small cell lung cancer: a dose finding study. Int J Radiat Oncol Biol Phys
1986;12: 379-383
20. Begg AC, Van der Kolk PJ, Dewit L, Bartelink H. Radiosensitization by cisplatin of RIF-I
tumour cells in vitro. Int J Radiat Oncol Biol Phys 1986;50:871-884
21. Dewit L, Oussoren Y, Bartelink H. Early and late damage in the mouse rectum after irradiation
and cis-diamminedichloro-platinum(II). Radiother Oncol 1987;8:57-69
22. Van Dongen JA, Bartelink H, Fentiman IS, Peterse JL. Ductal carcinoma in situ (DCIS) of the
breast - a therapeutic dilemma. Eur J Surg Oncol 1987;13:123 -125
23. Begg AC, Van der Kolk PJ, Emondt J, Bartelink H. Radiosensitization in vitro by cis-diammine
(1,1 cyclobutane-dicarboxylato) platinum (II) (carboplatin, JM8) and ethylenediammine-
malonatoplatinum (II) (JM40) Radiother Oncol 1987;9:157-165
24. Stewart FA, Oussoren Y, Luts A, Begg AC, Dewit L, Lebesque J, Bartelink H. Repair of
sublethal radiation injury after multiple small doses in mouse kidney: an estimate of flexure
dose. Int J Radiat Oncol Biol Phys 1987;13:765-772
25. Bartelink H. Radiotherapy in the management of early breast cancer: a review. Eur J Cancer
Clin Oncol 1988;24:77-82
26. Bartelink H. Combined Modality Treatment for Primary Tumor. NCI Monograph 1988;6:247-
251
27. Bartelink H, Bleehen NM, Phillips TL. Chemical modifiers. Int J Radiat Oncol Biol Phys
1988;14: S39-S49
28. Bartelink H, Borger JH, Van Dongen JA, Peterse JL. The impact of tumor size and histology
on local control after breast conserving therapy. Radiother Oncol 1988;11:297-303
29. Begg AC, Bartelink H, Stewart FA, Brown DM, Luck EE. Improvement of differential toxicity
between tumor and normal tissues using intratumoral injections with and without a slow drug
release matrix system. NCI Monograph 1988;6:133-136
30. Begg AC, Moonen L, Hofland I, Dessing M, Bartelink H. Human tumour cell kinetics using a
monoclonal antibody against iododeoxyuridine: Intratumour sampling variations. Radiother
Oncol 1988;11:337-347
31. Meertens H, Bartelink H, Minderhoud T. First clinical experience with a remote afterloading
system for low dose rate interstitial breast implants. Radiother Oncol 1988;11:387-393
32. Aaronson NK, Bartelink H, Van Dongen JA, Van Dam FSAM. Evaluation of breast conserving
therapy: clinical, methodological and psychosocial perspectives. Eur J Surg Oncol
1988;14:133-140
33. Peterse JL, Van Dongen JA, Bartelink H . Recurrence of breast carcinoma after breast
conserving treatment. Eur J Surg Oncol 1988;14:123-126
34. Stewart FA, Luts A, Oussoren Y, Begg AC, Dewit L, Bartelink H. Renal damage in mice after
treatment with cisplatin and X-rays: a comparison of fractionated and single dose studies. NCI
Monograph 1988; 6:23-27
35. Horiot JC, Van den Bogaert W, Ang KK, Van der Schueren E, Bartelink H, Gonzalez D, De
Page 9 of 26
Pauw M, Van Glabbeke M. Trials using radiotherapy with multiple fractions per day.
Radioterapia e trattamenti integrati 1988;17-25
36. Rubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R, Van der
Schueren E, Papadiamantis J, Vassilaros SD, Wildiers J, Winters PJ. Locally advanced breast
cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy. Eur J Cancer
Clin Oncol 1989;25; 4:667-678
37. Bartelink H, Borger JH, Van Dongen JA, Peterse JL. Reply to J. Staples. Radiother Oncol
1989;14:73-74
38. Stewart FA, Oussoren Y, Bartelink H. The influence of cisplatin on the response of mouse
kidneys to multifraction irradiation. Radiother Oncol 1989;15:93-102
39. Begg AC, Bohlken S, Bartelink H. The effect of cisplatin on the repair of radiation damage in
RIF1 mouse tumours in vivo. Radiother Oncol 1989;15:79-92
40. Dewit L, Oussoren Y, Bartelink H, Thames HD. The effect of cis-diamminedichloroplatinum (II)
on radiation damage in mouse rectum after fractionated irradiation. Radiother Oncol
1989;16:121-128
41. Bartelink H, Jassem J. Early presentation of results in clinical trials: an ethical dilemma for
medicine and science. Eur J Cancer 1990;26 (4);419-420
42. Bartelink H, Overgaard J. Inaugural editorial. Radiother Oncol 1990;19 ix
43. Meertens H, Van Herk M, Bijhold J, Bartelink H. First clinical experience with a newly
developed electronic portal imaging device. Int J Radiat Oncol Biol Phys 1990;18:1173-1181
44. Letschert JGJ, Lebesque JV, De Boer RW, Hart AAM, Bartelink H. Dose-volume correlation in
radiation-related late small-bowel complications:a clinical study. Radiother Oncol 1990;18;307-
320
45. Schaake-Koning C, Maat B, Van Houtte P, Van den Bogaert W, Dalesio O, Kirkpatrick A,
Bartelink H. Radiotherapy combined with low-dose Cis-Diammine Dichlotoplatinum (II)
(CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): A randomized three
arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. Int J
Radiat Oncol Biol Phys 1990;19:967-972
46. Deurloo MJM, Bohlken S, Kop W, Lerk CF, Hennink W, Bartelink H, Begg AC. Intratumoural
administration of Cisplatin in slow-release devices. Cancer Chemother Pharmacol
1990;27:135-140
47. Begg AC, Hofland I, Moonen L, Bartelink H, Schraub S, Bontemps P, Le Fur R, Van Den
Bogaert W, Caspers R, Van Glabbeke M, Horiot JC. The predictive value of cell kinetic
measurements in a European trial of accelerated fractionation in advanced head and neck
tumors: an interim report. Int J Radiat Oncol Biol Phys 1990;19:1449-1453
48. Deurloo MJM, Kop W, Van Tellingen O, Bartelink H, Begg AC. Intratumoural administration of
Cisplatin in slow-release devices. II. pharmacokinetics and intratumoural distribution. Cancer
Chemother Pharmacol 1991;27:347-353
49. Mijnheer BJ, Bartelink H, Bijhold J, Crabeels D, Gilhuijs KGA, Hoogervorst B, Pinkster M, Van
Herk MB, Vijlbrief R. The "QUIRT" project: quality control and real time imaging in radiation
therapy. Inter'l Society of Radiographers and Radiological Technicians (ISRRT)1991;27,1:29-
34
50. Bartelink H, Keus R. Progress in radiotherapy by treatment tailoring in head and neck cancer.
Current Opinion in Oncology 1991;3:523-529
51. Letschert JGJ, Gonzalez Gonzalez D, Oskam J, Koornneef L, Van Dijk JDP, Boukes R, Bras
J, Van Heerde P, Bartelink H. Results of radiotherapy in patients with stage I orbital non-
Hodgkin's lymphoma. Radiother Oncol 1991;22:36-44
52. Schaake-Koning C, Kirkpatrick A, Kröger, Van Zandwijk N, Bartelink H. The need for
immediate monitoring of treatment parameters and uniform assessment of patient data in
clinical trials. A quality control study of the EORTC Radiotherapy and Lung Cancer
Cooperative Groups. Eur J Cancer 1991;27(5):615-619
53. Bartelink H, Garavaglia G, Johansson KA, Mijnheer BJ, Van den Bogaert W, Van Tienhoven
G, Yarnold J. Report on a consensus meeting of the EORTC Radiotherapy and Breast Cancer
Cooperative Groups and the EUSOMA (European Society of Mastology) Quality Assurance in
conservative treatment of early breast cancer. Radiother Oncol 1991;22:323-326
54. Van Tienhoven G, Van Bree NAM, Mijnheer BJ, Bartelink H. Quality assurance of the EORTC
trial 22881/10882: "Assessment of the role of the booster dose in breast conserving therapy";
the dummy run. Radiother Oncol 1991;22:290-298
55. Bartelink H, Van der Schueren E, Van Glabbeke M, Pierart M. EORTC Trial protocol: The
conservative management of breast carcinoma by tumourectomy and radiotherapy: an
EORTC phase III study (22881/10882). Radiother Oncol 1991;22:v
Page 10 of 26
56. Stewart FA, Bartelink H, Van der Voet GB, De Wolff FA. Renal damage in mice after
sequential cisplatin and irradiation: The influence of prior irradiation on platinum elimination.
Radiother Oncol 1991;21:277-281
57. Schaake C, Van der Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P,
Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L,
Sculier JP, Van Zandwijk N, Bartelink H. Effects of concomitant cisplatin and radiotherapy on
inoperable non-small-cell lung cancer. N Eng J Med 1992;326;8:524-530
58. Van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, Van der Schueren
E, Sylvester R, Winter J, Van Zijl K. Randomized clinical trial to assess the value of breast-
conserving therapy in stage I and II breast cancer, EORTC 10801 trial. NCI Monographs
1992;11:15-18
59. Schaake-Koning C, Bartelink H, for the Lung Cancer and Radiotherapy Cooperative Groups of
the European Organization for Research and Treatment of Cancer Treatment of non-small-
cell lung cancer with cisplatinum and radiotherapy (Correspondence reply). N Eng J Med
1992;327:432-433
60. Begg AC, Hofland I, Van Glabbeke M, Bartelink H, Horiot JC. Predictive value of potential
doubling time for radiotherapy of head and neck patients: results from the EORTC
Cooperative Trial 22851. Semin Radiat Oncol 1992;2;1:22-25
61. Van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, Van der Schueren
E, Sylvester R, Tong D, Winter J, Van Zijl K. Factors influencing local relapse and survival and
results of salvage treatment after breast-conserving therapy in operable breast cancer:
EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II
breast cancer. Eur J Cancer 1992;28a;415:801-805
62. Verniers D, Bartelink H. Het retroperitoneaal paraganglioom.Tijdschr voor Geneeskunde
(Belgium) 1992;48;18:1321-1325
63. Borger JH, Van Tienhoven G, Passchier DH, Hart AAM, Van Dongen JA, Rutgers EJTh,
Bartelink H. Primary radiotherapy of breast cancer: Treatment results in locally advanced
breast cancer and in operable patients selected by positive axillary apex biopsy. Radiother
Oncol 1992;25:1-11
64. Russell NS, Bartelink H. Optimized radiotherapy for head and neck cancer. Current Opinion in
Oncology 1992;4:491-498
65. Verniers DA, Keus RB, Schouwenburg PF, Bartelink H. Radiation therapy, an important mode
of treatment for head and neck chemodectomas. Eur J Cancer 1992;28a;6/7:1028-1033
66. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen F, Hoogenhout J, Van Houtte P,
Kirkpatrick A, Koolen M, Maat B, Nijs A, Resaud A, Rodrigus P, Schuster-Uitterhoeve L,
Sculier J, Van Zandwijk N, Bartelink H. Radiotherapy combined with low-dose cisplatin; results
of the EORTC 08844 Phase III study by the EORTC Radiotherapy and Lung Cancer
Cooperative Groups. Lung Cancer 1993;9:245-248
67. Zoetmulder FAN, Borger JH, Rutgers EJT, Bergman R, Peterse J, Bartelink H. Breast
conserving therapy in patients with relatively large (T2, T3) breast cancers by preoperative
irradiation and myocutaneous LD flap reconstruction. A new technique in breast conservation.
Eur J Cancer 1993;29a;7:957-961
68. Russell NS, Bartelink H, Snow GB. Letter to the Editor: Head and neck cancer. N Eng J Med
1993;328;24:1783-1784
69. El-Gayed AAH, Bel A, Vijbrief R, Bartelink H, Lebesque JV. Time trend of patient setup
deviations during pelvic irradiation using electronic portal imaging. Radiother Oncol
1993;26:162-171
70. Gregoire V, Begg AC, Huiskamp R, Verrijk R, Bartelink H. Selectivity of boron carriers for
boron neutron capture therapy: pharmacological studies with boroncaptate sodium, L-
oronophenylalanine and boric acid in murine tumors. Radiother Oncol 1993;27:46-54
71. Bartelink H, Bernier J, Garavaglia G, Kurtz J. Foreword (Consensus meeting on High
dose/high precision radiotherapy consensus meeting, Geneva, January 15 and 16, 1993.
Radiother Oncol 1993;29:xi-xii
72. Horiot JC, Van der Schueren E, Johansson KA, Bernier J, Bartelink H. The programme of
quality assurance of the EORTC Radiotherapy Group. A historical overview. Radiother Oncol
1993;29:81-84
73. Horiot JC, Bernier J, Johansson KA, Van der Schueren E, Bartelink H. Session I: Minimum
requirements for quality assurance in radiotherapy. Radiother Oncol 1993;29:103-104
74. Bel A, Van Herk M, Bartelink H, Lebesque JV. A verification procedure to improve patient
setup accuracy using portal images. Radiother Oncol 1993;29:253-260
75. Begg AC, Deurloo MJM, Kop W, Bartelink H. Improvement of combined modality therapy with
Page 11 of 26
cisplatin and radiation using intratumoral drug administration in murine tumors. Radiother
Oncol 1994;31:129-137
76. Bosset J-F, Pelissier EP, Maniion G, Pavy J-J, Horiot J-C, Hamers HP, Bartelink H. Plea for a
preoperative adjuvant approach in the management of rectal cancer. Int J Radiat Oncol Biol
Phys 1994;29;1:205-208
77. Sylvester R, Bartelink H, Rubens R. A reversal of fortune: practical problems in the monitoring
and interpretation of an EORTC breast cancer trial. Statistics in Medicine 1994;13:1329-1335
78. Bel A, Bartelink H, Vijlbrief R, Lebesque JV. Transfer errors of planning CT to simulator: a
possible source of setup inaccuracies? Radiother Oncol 1994;31:176-180
79. Borger J, Kemperman H, Hart G, Peterse H, Van Dongen J, Bartelink H. Risk factors in breast
conservation therapy. J Clin Oncol 1994;12:653-660
80. Letschert JGJ, Lebesque JV, Aleman BMP, Bosset JF, Horiot JC, Bartelink H, Cionini L, et al.
The volume effect in radiation-related late small bowel complications: results of a clinical study
of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.
Radiother Oncol 1994;32:116-123
81. Moonen LMF, Horenblas S, van der Voet JCM, Nuyten MJC, Bartelink H. Bladder
conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using
combination therapy of surgery and iridium-192 implantation. British J Urology 1994;74:322-
327
82. Moonen L, Bartelink H. Fractionation in radiotherapy. Cancer Treatment Reviews
1994;20:365-378
83. Van den Brekel MWM, Bartelink H, Snow GB. The value of staging of neck nodes in patients
treated with radiotherapy. Radiother Oncol 1994;32:193-196
84. Borger JH, Kemperman H, Smitt HS, Hart A, Van Dongen J, Lebesque J, Bartelink H. Dose
and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol
Phys1994;30; 5:1073-1081
85. Smeets MFMA, Mooren EHM, Abdel-Wahab AHA, Bartelink H, Begg AC. Differential repair of
radiation induced DNA damage in human squamous carcinoma cells and the effect of caffeine
and cysteamine on DNA double strand-break induction and repair. Radiat Res 1994:140:153-
160
86. Coco-Martin JM, Smeets MFMA, Poggensee M, Mooren E, Hofland I, Vandenbrug M,
Ottenheim C, Bartelink H, Begg AC. Use of fluorescence in situ hybridization to measure
chromosome aberrations as a predictor of radiosensitivity in human tumour cells. Int J Radiat
Oncol Biol Phys1994;66:297-307
87. Ptaszynski A, Van den Bogaert W, Van Glabbeke M, Piccart M, Bartelink H, Horiot JC,
Fourquet A, Struikmans H, Hamers H, Müller RP, Hoogenraad WJ, Jager JJ, Van der
Schueren E. Patient population analysis in EORTC trial 22881/10882 on the role of a booster
dose in breast-conserving therapy. Eur J Cancer 1994;30a:2073-2082
88. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P,
Kirkpatrick A, Koolen M, Maat B, Nijs A, Resaud A, Rodrigus P, Schuster-Uitterhoeve L,
Sculier J, Van Zandwijk N, Bartelink H. Radiosensitization by cytotoxic drugs. The EORTC
experience by the radiotherapy and lung cancer cooperative groups. Lung Cancer
1994;10:S263-S270
89. Rutgers EJ, Peterse JL, Bartelink H, Van Dongen JA. Surgical treatment and deciding
definitive management policy in a premenopausal patient with early breast cancer. Eur J Surg
Oncol 1994; 20:607-609
90. Bosset JF, Pelissier E, Mantion G, Pavy JJ, Horiot JC, Hamers HP, Bartelink H. Letter to the
Editor: In response to Mclean and Duncan. Int J Radiat Oncol Biol Phys 1995;31; 4:1024
91. Overgaard J, Bartelink H. Editorial: About tolerance and quality. An important notice to all
radiation oncologists. Radiother Oncol 1995;35:1-3
92. Rubin P, Constine LS, Fajardo LF, Philips TL, Wasserman TH, Bartelink H, Denekamp J,
Horiot JC, Mornex F, Overgaard J, Pavy JJ. Late effects consensus conference:
RTOG/EORTC. Radiother Oncol 1995;35:5-7
93. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, Gonzales-Gonzales D,
Horiot JC, Bolla M, Bartelink H. EORTC late effects working group: Late effects toxicity
scoring: the SOMA scale. Radiother Oncol 1995;35:11-15
94. Aleman BMP, Bartelink H, Gunderson LL. The current role of radiotherapy in colorectal
cancer. Eur J Cancer 1995;31a:1333-1339
95. Bolla M, Bartelink H, Garavaglia G, Gonzalez Gonzalez D, Horiot JC, Johansson KA, Van
Tienhoven G, et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy.
Radiother Oncol 1995;36:1-8
Page 12 of 26
96. Russell NS, Arlett CF, Bartelink H, Begg AC. Use of fluorescence in situ hybridization to
determine the relationship between chromosome aberrations and cell survival in eight human
fibroblast strains. Int J Radiat Oncol Biol Phys 1995;68;2:185-196
97. Kemperman H, Borger J, Hart AAM, Peterse H, Bartelink H, Van Dongen J. Prognostic factors
for survival after breast conserving therapy for stage I and stage II breast cancer; the role of
local recurrence. Eur J Cancer 1995; 31A:690-698
98. Van Tienhoven G, Borger JH, Passchier DH, Hart AAM, Rutgers EJTh, Van Dongen JA,
Bartelink H. The prognostic significance of the axillary apex biopsy in clinically operable breast
cancer. Eur J Cancer 1995;31a;12 :1965-1968
99. Abe K, Enomoto K, Hattori T, Bartelink H, et al. Effects of radiotherapy and surgery in early
breast cancer - an overview of the randomized trials. N Eng J Med 1995;333:1444-1455
100. Jassem J, Bartelink H. Chemotherapy in locally advanced head and neck cancer: a critical
reappraisal. Cancer Treatment Review 1995;21:447-462
101. Rubin P, Constine LS, Fajardo LF, Philips TL, Wasserman TH, Bartelink H, Denekamp J,
Horiot JC, Mornex F, Overgaard J, Pavy JJ. Introduction: Joint statement of mission by the
RTOG/EORTC working groups. Int J Radiat Oncol Biol Phys 1995;31:1037-1039
102. Coco-Martin JM, Ottenheim CPE, Bartelink H, Begg AC. Lethality of radiation-induced
chromosome aberrations in human tumour cell lines with different radiosensitivities. Int J
Radiat Oncol Biol Phys 1996;69;3:337-344
103. Borger J, Bartelink H. Does the sequence of radiotherapy and chemotherapy in breast-
conserving therapy influence outcome?Cancer J 1996;2;1:19-20
104. Schuster-Uitterhoeve ALJ, van der Vaart PJM, Schaake-Koning CCM, Benraadt T, Koolen
MGJ, González González D, Bartelink H. Feasibility of escalation daily doses of cisplatin in
combination with accelerated radiotherapy in non small cell lung cancer. A study conducted
under auspices of the EORTC Lung Cancer Cooperative and Radiotherapy Group. Eur J
Cancer 1996;32a;8:1314-1319
105. Bartelink H, Jassem J. Editorial: Post-operative radiotherapy in non-small-cell lung cancer:
more questions than answers. British J Cancer 1996;74:495
106. Bartelink H, Mijnheer B, Dewit L. Editorial: Is there a future for neutron capture therapy? Int J
Radiat Biol 1996;36;1:267-268
107. Lara PC, Russell NS, Smolders IJH, Bartelink H, Begg AC, Coco-Martin JM, Radiation-
induced differentiation of human skin fibroblasts: relationship with cell survival and collagen
production. Int J Radiat Biol 1996;70;6:683-692
108. Denekamp J, Bartelink H, Rubin P. Correction for the use of the SOMA LENT tables.
American and European LENT Working Committees. (Letter to the Editor). Radiother Oncol
1996;39:191
109. Denekamp J, Bartelink H, Rubin P. Correction for the use of the SOMA LENT tables. (Letter
to the Editor). Int J Radiat Oncol Biol Phys 1996;35:417
110. Berner J, Horiot JC, Bartelink H, Johansson KA, Cionini L, Gonzalez DG, Hamers H, Van den
Bogaert W. Profile of radiotherapy departments contributing to the Cooperative Group of
Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J
Radiat Oncol Biol Phys 1996;34:953-960
111. Ricke J, Van der Donk E, Wolf M, Ostendorf B, Hosten N, Zielinski C, Liebig T, Stroszczinski
C, Lopez-Hanninen E, Lemke AJ, Gillessen C, Gurvit O, Amthauer H, Kleinholz L, Bartelink H,
Felix R. Second opinion in on-line radiology via Internet: report on implementation and
analysis of reliability of findings in sectional images. Aktuelle Radiol 1997;7:50-55
112. Bartelink H, Rubens RD, Van der Schueren E, Sylvester R. Hormonal therapy prolongs
survival in irradiated locally advanced breast cancer. A European Organization for Research
and Treatment of Cancer (EORTC) randomized phase-III trial. J Clin Oncol 1997;15;1:207-
215
113. Bosset JF, Pavy JJ, Roelofsen F, Bartelink H. For the EORTC Radiotherapy and
Gastrointestinal Cooperative Groups. Correspondence: Combined radiotherapy and
chemotherapy for anal cancer. Lancet 1997;349:205
114. Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofsen F, Pene F, Gerard A,
Einhorn N, Nguyen TD, Vanglabbeke M, Scalliet on behalf of the EORTC Neoplasia in the
Elderly Study Group. Age is not a limiting factor for radical radiotherapy in pelvic malignancies.
Radiother Oncol 1997;42:107-120
115. Bartelink H, Roelofsen F, Eschwege F, Rougier Ph, Bosset JF, Gonzalez Gonzalez D, Pfeiffert
D, Van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy superior to
radiotherapy alone in the treatment of locally advanced anal cancer. Results of a phase III
randomized trial of the EORTC Radiotherapy and Gastrointestinal Cooperative Groups. J Clin
Page 13 of 26
Oncol 1997;15; 5:2040-2049
116. Moonen L, Van der Voet H, Horenblas S, Bartelink H. A feasibility study of accelerated fraction
in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Biol 1997;37; 3:537-542
117. Van Tienhoven, G, Mijnheer BJ, Bartelink H, González D. Quality assurance of the EORTC
trial 22881/10882: Boost versus no boost in breast conserving therapy. Strahlenther Onkol
1997;173: 201-207
118. Haas RLM, Keus RB, Loftus BM, Rutgers EJTh, Van Coevorden F, Bartelink H, on behalf of
the Soft Tissue Tumours Working Group. The role of radiotherapy in the local management of
dermatofibrosarcoma protuberans. Eur J Cancer 1997;33;7:1055-1060
119. Rasch C, Keus R, Pameijer FA, Koops W, de Ru V, Muller S, Touw A, Bartelink H, van Herk
M, Lebesque JV. The potential impact of CT-MRI matching on tumor volume delineation in
advanced head and neck cancer. Int J Radiat Biol 1997;39,4:841-848
120. Verheij M, Ruiter GA, Zerp SF, van Blitterswijk WJ, Fuks Z, Haimovitz-Friedman A, Bartelink
H. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-
induced apoptosis. Radiother Oncol 1998;47; 3:225-232
121. Curran D, Van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, Bartelink H on
behalf of the EORTC Breast Cancer Coop. Group (BCCG). Quality of life of early-stage breast
cancer patients treated with radical mastectomy or breast-conserving procedures: results of
EORTC trial 10801. Eur J Cancer 1998;34;3:307-314
122. Verheij M, Ruiter GA, Zerp SF, van Blitterswijk WJ, Fuks Z, Haimovitz-Friedman A, Bartelink
H. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-
induced apoptosis. Radiother Oncol 1998;47:225-232
123. Russell NS, Grummels A, Hart AAM, Smolders IJH, Borger J, Bartelink H, Begg AC. Low
predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following
radiotherapy for breast cancer. Int J Radiat Biol 1998;73:661-670
124. Van der Vaart PJ, Van der Vange N, Zoetmulder FAN, Van Goethem AR, Van Tellingen O,
Ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with
regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA
adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-154
125. Bartelink H, Dewit L, Roelofsen F, Bosset JF. Reply to Letter to the Editor: Is concomitant
radiotherapy and chemotherapy superior to optimal radiotherapy alone? J Clin Oncol 1998;16;
2: 802-803
126. Recht A, Bartelink H, Fourquet A, Fowble B, Harris JR, Kurtz J, McCormick B, Olivotto IA,
Rutqvist L, Solin LJ, Yarnold J. Postmastectomy Radiotherapy: Questions for the Twenty-First
Century. J Clin Oncol 1998;16;8:2886-2889
127. Ricke J, van der Donk E, Wolf M, Ostendorf B, Hosten N, Zielinski C, Liebig T, Stroszcinski C,
Lopez-Hanninen E, Lemke AJ, Gillessen C Gurvit O, Amthauer H, Kleinholz L, Bartelink H,
Felix R. Die “Zweite Meinung” in der Radiologie Online uber das Internet: Bericht uber die
Implementierung und Analyse der Befundungssicherheit von Schnittbildern. Akt Radiol
1998;7:50-55
128. Van der Voet JCM, Keus RB, Hart AAM, Hilgers FJM, Bartelink H. The impact of treatment
time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol
Biol Phys 1998; 42;2:247-255
129. Moonen L, van der Voet H, de Nijs R, Horenblas S, Hart AAM, Bartelink H. Muscle-invasive
bladder cancer treated with external beam radiation: influence of total dose, overall treatment
time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 1998;42;3:525-
530
130. Verheij M, van Blitterswijk WJ, Bartelink H. Radiation-Induced Apoptosis The Ceramide-
SAPK signaling pathway and clinical aspects.Acta Oncologica 1998;37:575-581
131. Moonen L, van der Voet H, de Nijs R, Hart AAM, Horenblas S, Bartelink H. Muscle-invasive
bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and
the predictive value of cytoscopic re-evaluation during treatment. Radiother Oncol
1998;49:149-155
132. Roelofsen F, Bartelink H. Combined modality treatment of anal carcinoma. Oncologist 1998;3;
413-418
133. Van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, Sylvester R,
Fentiman IS, van der Schueren E, van Zijl, Blichert-Toft, Bartelink H, van Dongen JA, on
behalf od the EORTC Breast Cancer Coop. Group and the Danish Breast Cancer Cooperative
Group. Prognosis after treatment for loco-regional recurrence after mastectomy or breast
conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). Eur J Cancer
1999;35;1:32-38
Page 14 of 26
134. Verdonck-de Leeuw IM, Hilgers, FJM, Keus RB, Koopmans-van Beinum FJ, Greven AJ, de
Jong JMA, Vreeburg G, Bartelink H. Multidimensional assessment of voice characteristics
after radiotherapy for early glottic cancer. Laryngoscope 1999;109:241-248
135. Towards prediction and modulation of treatment response. Bartelink H, Begg A, Coco Matin J,
van Dijk M, van ‘t Veer L, van der Vaart P, Verheij M. RadiotherOncol 1999;50:1-11
136. Bartelink H, Roelofsen F, Eschwege F, Rougier Ph, Bosset JF, Gonzalez Gonzalez D, Pfeiffert
D, Van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy superior to
radiotherapy alone in the treatment of locally advanced anal cancer. Results of a phase III
randomized trial of the EORTC Radiotherapy and Gastrointestinal Cooperative Groups 1997,
1999 by American Society of Clinical Oncology Classic Papers and Current comments
1999;3;2:529-538
137. Begg AC, Haustermans K, Hart AAM, Disch S, Saunders M, Zackrisson B, Gustaffson H,
Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink
H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski,
Dobrowsky, Struikmans H, Rutgers D, Wilson GD. The value of pretreatment cell kinetic
parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter
analysis. Radiother Oncol 1999;50: 13-23
138. Bartelink H. Commentary: Is neoadjuvant chemotherapy the answer for bladder cancer?
Lancet 1999;354:526-527
139. Verdonck-de Leeuw IM, Keus R, Hilgers FJM, Koopmans-van Beinum FJ, Greven AJ, de
Jong JMA, Vreeburg G, Bartelink H. Consequences of voice impairment in daily life for
patients following radiotherapy for early glottic cancer: voice quality, vocal function, and vocal
performance. Int J Radiat Oncol Biol Phys 1999;44;5:1071-1078
140. Coco Martin JM, Mooren E, Ottenheim C, Burrill W, Nunez MI, Sprong D, Bartelink H, Begg
AC. Potential of radiation-induced chromosome aberrations to predict radiosensitivity in
human tumour cells. Int J Radiat Oncol Biol Phys 1999;75;9:1161-1168
141. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyl-Lysophospholipids
activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Research
1999;59:2457-2463
142. Vrieling C, Collette L, Bartelink E, Borger J, Brenninkmeyer SJ, Horiot JC, Pierart M,
Poortmans PM, Struikmans H, van der Schueren E, Van Dongen JA, van Limbergen E,
Bartelink H on behalf of the EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Validation of the methods of cosmetic assessment after breast-conserving therapy in the
EORTC "Boost versus no boost" trial. Int J Radiat Oncol Biol Phys 1999;45;3; pp 667-676
143. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JS, Jager JJ, Pierart M, Poortmans
PM, Struikmans H, van der Hulst M, van der Schueren E, Bartelink H. The influence of the
boost in breast-conserving therapy on cosmetic outcome in the EORTC "Boost versus no
boost" trial. Int J Radiat Oncol Biol Phys 1999;45;3:677-685
144. Russell NS, Bartelink H. Radiotherapy: the last 25 years. Cancer Treat Rev 1999;25;6:365-
376
145. Ptaszynski AM, Van den Bogaert W, Horiot JC, Poortmans P, Fourquet A, Struikmans H,
Bartelink H, Pierart M, Collette L, van der Schueren E. Radiation dose homogeneity in an
EORTC multicenter trial on breast irradiation. Acta Oncol 1999;38;13:19-27
146. Russell NS, Lara PC, Grummels A, Hart AAM, Coco-Martin JM, Bartelink H, Begg AC. In vitro
differentiation characteristics of human skin fibroblasts: correlations with radiotherapy-induced
breast fibrosis in patients. Int J Radiat Oncol Biol Phys 2000;76;2:231-240
147. Julien JP, Bijker N, Fentiman I, Peterse JL, Delledonne V, Rouanet Ph, Avril A, Sylvester R,
Mignolet F, Bartelink H, van Dongen J, on behalf of EORTC Breast Cancer and Radiotherapy
Coop. Groups. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first
results of EORTC randomised phase III trial 10853. Lancet 2000;355:528-533
148. Bartelink H, Begg AC, CoCo Martin J, van Dijk M, Moonen L, van 't Veer LJ, van de Vaart P,
Verheij M. Translational research offers individually tailored treatments for cancer patients.
Cancer J Scientific American 2000;6;1:2-10
149. Van der Vaart JM, Belderbos J, de Jong D, Sneeuw KCA, Majoor D, Bartelink H, Begg AC.
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and
radiotherapy. Int J Cancer 2000;89:160-166
150. Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT,Benraadt J, Koning
CC, Gonzalez Gonzalez D, Bartelink H. Toxicity of high-dose radiotherapy combined with daily
cisplatin in non-small cell lung cancer results of the EORTC 08912 phase I/II study. Eur J
Cancer 2000;36;5:592-600
151. Ricke J, Bartelink H. Telemedicine and its impact on cancer management. Eur J Cancer
Page 15 of 26
2000; 36;5:826-833
152. Jansen EPM, Dewit LGH, van Herk M, Bartelink H. Target volumes in radiotherapy for high-
grade malignant glioma of the brains. Radiother Oncol 2000;56:151-156
153. Early Breast Trialists' Collaborative Group. Favourable and unfavourable effects on long-term
survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet
2000;335:1757-1770
154. Bartelink H, Horiot JC. Factors in decision making in the treatment of breast cancer.
Radiother Oncol 2000;55:217-218
155. Van Dongen JA, Voogd A, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren
E, Helle PA, van Zijl K, Bartelink H. Long-term results of a randomized trial comparing breast-
conserving therapy with mastectomy: European Organization for Research and Treatment of
Cancer. Journal Nat Cancer Institute 2000;92;14:1143-1150
156. Jansen EPM, Keus RB, Hilgers FJM, Haas RLM, Tan IB, Bartelink H. Does the combination of
radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat
Oncol Biol Phys 2000;48;1:27-35
157. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue res 2000;301;1:133-142
158. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M,
Poortmans PM, Struikmans H, Maat B, Van Limpbergen E, Bartelink H, on behalf of the
EORTC Radiotherapy and Breast Cooperative Groups. The infuence of patient, tumor and
treatment factors on the cosmetic results after breast-conserving therapy in the EORTC
'boost vs no boost' trial. Radiother Oncol 2000;55:219-232
159. Bartelink H. Post-mastectomy radiotherapy: recommended standards. Annals of Oncology
2000;11:7–11
160. Overgaard J, Bartelink H. Correspondence: Breast cancer survival advantage with
radiotherapy. Lancet 2000;356:1269-1270
161. Schornagel JH, Verheij M, Bartelink H. Concurrent chemotherapy and radiation for locally
advanced squamous cell cancers: What is the schedule of choice? Cur Onc Rep 2001;3:1-2
162. Bartelink H. From translational research to improved local control and survival: the Gilbert
Fletcher award lecture, Lugano, March 2000. Int J Radiat Oncol Biol Phys 2001;49(2):311-318
163. Voogd AC, Nielsen M, Peterse JL, et al (Bartelink H), for the Danish Breast Cancer Coop.
Group and the Breast Cancer Coop. Group of the EORTC. Differences in risk factors for local
and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast
cancer: Pooled results of two large European randomized trials. J Clin Oncol 2001;19;6:1688-
1697
164. Moonen L, Ong F, Gallee M, Verheij M, Horenblas S, Hart G, Bartelink H. Apoptosis,
proliferation and p53 Cyclin D1, and retinoblastoma gene expression in relation to radiation
response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys
2001;49;5:1305-1310
165. Dewit LGH, Jansen EPM, Van Herk M, Bartelink H. Reply to letter by Chien et al on Clinical
Target volume of high-grade glioma. Radiother Oncol 2001;58:219-220
166. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet
A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, for the EORTC Radiotherapy and
Breast Cancer Groups. Recurrence rates after treatment of breast cancer with standard
radiotherapy with or without additional radiation. N Eng J Med 2001;345;19:1378-1387
167. Bartelink H. Commentary on the paper “A preliminary report of intraoperative radiotherapy
(IORT) in limited-stage breast cancers that are conservatively treated.” A critical review of an
innovative approach. Eur J Cancer 2001;37:2143-2146
168. Bosset JF, Horiot JS, Hamers HP, Cionini L, Bartelink H, Caspers R, Untereiner M,
Ciambelloti E, Pierart M, Van Glabbeke M. Postoperative pelvic radiotherapy with or without
elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical
trial of the EORTC Radiotherapy Group. Radiother Oncol 2001;61:7-13
169. Ong F, Moonen LMF Gallee MPW, ten Bosch C, Zerp SF, Hart AAM, Bartelink H, Verheij M.
Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and
p53. Radiother Oncol 2001;61:169-175
170. Bartelink H, Schellens JHM, Verheij M. The combined use of radiotherapy and chemotherapy
in the treatment of solid tumours. Eur J Cancer 2002;38:216-222
171. Bartelink H, Horiot JC. The autors reply: Recurrence rates after treatment of breast cancer
with standard radiotherapy with or without additional radiation. N Eng J Med 2002;346;11:862
172. Bartelink H, Van den Bogaert W, Horiot J-C, Jager J, van Glabbeke M. Concomitant cisplatin
and radiotherapy in a conventional and modified fractionation schedule in locally advanced
head and neck cancer: A randomized phase II EORTC trial. Eur J Cancer 2002;38:667-673
Page 16 of 26
173. Vens C, Dahmen-Mooren, Verwijs-Janssen, Blyweert W, Graversen L, Bartelink H, Begg AC.
The role of DNA polymerase ß in determining sensitivity to ionising radiation in human tumor
cells. Nucleic Acids Research 2002;30;13:2995-3004
174. van der Vijver MJ, He YD, van ‘t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse
JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A,. Glas A, Delahaye L, van der
Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression
signature as a predictor of survival in breast cancer. N Eng J Med 2002;347;25:1999-2009
175. Cho BS, van Herk M, Mijnheer BJ, Bartelink H. The effect of set-up uncertainties, contour
changes, and tissue inhomogeneities on target dose-volume histograms. MedPhys 2002;29;
10:2305-2318
176. Vrieling C, Fourquet A, Hoogenraad WJ, Horiot J-C, Jager JJ, Bing Oei S, Peterse HL, Pierart
M, Poortmans PM, Struikmans H, van den Bogaert W, Bartelink H on behalf of the EORTC
Radiotherapy, Breast Cancer Groups. Can patient-, treatment- and pathology-related
characteristics explain the high local recurrence rate following breast-conserving therapy in
young patients? Eur J Cancer 2003;39:932-944
177. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-
lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Anticancer Drugs 2003;14;2:167-173
178. Haas RLM, Poortmans Ph, de Jong D, Aleman BMP, Dewit LGH, Verheij M, Hart AAM, van
Oers MHJ, van der Hulst M, Baars JW, Bartelink H. High response rates and lasting
remissions after low dose involved field radiotherapy in indolent lymphomas. J Clin Oncol
2003;21;13:2474-2480
179. Van der Hage JA, Putter H, Bonnema J, Bartelink H, Therasse P, van de Velde CJH, on
behalf of the EORTC Breast Cancer Group.Impact of locoregional treatment on early-stage
breast cancer patienten: a retrospective analysis. Eur J Cancer 2003;39:2192-2199
180. Bartelink H. Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a
standard? The Breast 2003;12:475-482
181. Klein Zeggelink WF, Deurloo EE, Bartelink H, Rutgers EJ, Gilhuijs KG.Reproducibility of the
assessment of tumor extent in the breast using multiple image modalities.Med Phys 2003;30
(11):2919-26
182. Haas RL, Valdes-Olmos RA, Hoefnagel CA, Verheij M, de Jong D, Hart AA, Bartelink H.
Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in
follicular lymphoma patients. Radiother Oncol 2003;69(3):323-328
183. Bartelink H, Benz C, Cleveland D, Dorn R, Gralow J, Gradishar WJ, Grant K, Heimann R,
Hellman S, Hudis C, Kerbel R, Lippman M, Lung J, Posner MC, Steeg P, Vestal R,
Weichselbaum RR, Zetter B. Expedition Inspiration Fund for Breast Cancer Research Meeting
2003. Breast Cancer Res Treat 2003;80(2):139-44
184. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van
Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J
Clin Oncol 2003;15;21(18):3431-3439
185. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJ, Christensen L, Denis
L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler
M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-
Moreno JM, Bishop JN, Oleari F, Perrin P, Quinn M, Richards M, Ringborg U, Scully C,
Siracka E, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG,
Zatonski W, zur Hausen H. European Code Against Cancer and scientific justification: third
version (2003). Ann Oncol 2003;14;7:973-1005
186. Tytgat GNJ, Bartelink H, Bernards R, Giaccone G, van Lanschot JJB, Offerhaus GJA, Peters
GJ. Cancer of the Esophagus and Gastric Cardia: Recent Advances Diseases. Esophagus
2004;17:10-26
187. Nieweg OE, Bartelink H. Implications of lymphatic mapping for staging and adjuvant treatment
of patients with breast cancer. Eur J Cancer 2004;40:179-181
188. Aleman BMP, Russell NS, Bartelink H, van Leeuwen FE. Correspondence reply re: Radiation
therapy in the treatment of Hodgkin’s disease: Do you see what I see? by Thomas H. Huxley
(1825-1895) J National Cancer Institute 2004;97;3:235-236
189. Bartelink H. Intraoperative radiotherapy for breast cancer: tail wagging the dog? Lancet Oncol
2004;5;4:207-808
190. Cho BC, Schwarz M, Mijnheer BJ, Bartelink H. Simplified intensity-modulated radiotherapy
using pre-defined segments to reduce cardiac complications in left-sided breast cancer.
Radiother Oncol 2004;70;3:231-41
191. Cho BC, Mijnheer BJ, Bartelink H. Determining optimal two-beam axial orientations for heart
Page 17 of 26
sparing in left-sided breast cancer patients. Med Phys 2004;31;1:111-121
192. Poortmans P, Bartelink H, Horiot JC et al. The influence of the boost technique on local
control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.
Radiother Oncol 2004;72;1:25-33
193. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis
in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004;1;59;3:782-787
194. Pos FJ, Horenblas S, Lebesque J, Moonen L, Schneider C, Sminia P, Bartelink H. Low-dose-
rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat
Oncol Biol Phys 2004;1;59(3):696-705
195. Artignan X, Smitsmans MH, Lebesque JV, Jaffray DA, van Her M, Bartelink H. Online
ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on
prostate displacement. Int J Radiat Oncol Biol Phys 2004;1;59(2):595-601
196. Wallner P, Arthur D, Bartelink H, et al. Workshop on partial breast irradiation: state of the art
and the science, Bethesda, MD, December 8-10, 2002. J Natl Cancer Inst 2004;96(3):175-184
197. Russell NS, Bartelink H. Sophisticated radiotherapy with optimal surgery is the way forward.
Cur Opin Oncol 2004;16(6):529-535
198. Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van ‘t
Veer L, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and
integration of a wound-response gene expression signature in predicting breast cancer
survival. The National Academy of Sciences of the USA 2005;8;102(10):3738-43
199. Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder
cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? Int J
Radiat Oncol Biol Phys 2005;1;61(3):678-86
200. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, Strom EA, Pierce LJ, Marks
LB, Bartelink H, et al. Long-term outcome after breast-conservation treatment with radiation
for mammographically detected ductal carcinoma in situ of the breast. Cancer
2005;103(6):1137-1146
201. Dorresteijn LD, Kappelle AC, Scholz NM, Munneke M, Scholma JT, Balm AJ, Bartelink H,
Boogerd W. Increased carotid wall thickening after radiotherapy on the neck. Eur J Cancer
2005;41(7):1026-30
202. Poortmans PM, Ataman F, Bernard Davis J, Bartelink H, Horiot JC, Pierart M, Collette L, Van
Tienhoven G. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial
for breast conserving therapy: Comparison of the results of two individual case reviews
performed early and late during the accrual period. Radiother Oncol 2005;76(3):278-84
203. Boyle P, Ariyaratne M, Bartelink H, Baselga J, et al. Curbing tobacco's toll starts with the
professionals: World No Tobacco Day. Lancet 2005;365(9476):1990-2
204. Dorresteijn LD, Marres HA, Bartelink H, Kappelle LJ, Boogerd W, Kappelle AC. Radiotherapy
on the neck as a risk factor for stroke. Ned Tijdschr Geneeskd 2005;4;149(23):1249-53
205. Haas RL, Poortmans P, de Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H.
Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory
non-follicular lymphoma patients. Eur J Cancer 2005;41(12):1724-30
206. Valentini V, Glimelius B, Minsky BD, Van Cutsem E, Bartelink H, Beets-Tan RG, Gerard JP,
Kosmidis P, Pahlman L, et al. The multidisciplinary rectal cancer treatment: Main
convergences, controversial aspects and investigational areas which support the need for an
European Consensus. Radiother Oncol 2005;76(3):241-50
207. Solin LJ, Fourquet A, Vicini FA, Taylor M, Haffty B, Strom EA, Wai E, Pierce LJ, Marks LB,
Bartelink H, Campana F, McNeese MD, et al. Salvage treatment for local or local-regional
recurrence after initial breast conservation treatment with radiation for ductal carcinoma in
situ. Eur J Cancer 2005;41(12):1715-23
208. Deurloo EE, Klein Zeggelink WF, Teertstra HJ, Peterse JL, Rutgers EJ, Muller SH, Bartelink
H, Gilhuijs KG. Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving
therapy: complementary value for subgroups of patients. Eur Radiol 2006;16(3):692-701
209. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated
loco-regional recurrence of breast cancer is more common in young patients and following
breast conserving therapy: long-term results of European Organisation for Research and
Treatment of Cancer studies. Eur J Cancer 2006;42(3):351-6
210. Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D,
Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D,
Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A,
Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo
KY, Zatonski W, Zhao P. Tobacco: deadly in any form or disguise. Lancet
Page 18 of 26
2006;27;367(9524):1710-2
211. Bartelink H. Partial breast irradiation: Is it a valid option? Breast 2006;15(3):297-9
212. EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I,
Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. EORTC
Breast; Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ:
ten-year results of European Organisation for Research and Treatment of Cancer randomized
phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC
Radiotherapy Group.Cancer Cooperative Group. J Clin Oncol 2006;20;24(21):3381-7
213. Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, Schellens JH, Begg AC. Prediction of
treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and
neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J
Cancer 2006;15;119(4):750-6
214. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ, Bartelink H,
Brown PO, Chang HY, van de Vijver MJ. Predicting a local recurrence after breast-conserving
therapy by gene expression profiling. Breast Cancer Res 2006;8(5):R62
215. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ. Gene
expression profiles of primary breast carcinomas from patients at high risk for local recurrence
after breast-conserving therapy. Clin Cancer Res 2006;1;12(19):5705-12
216. Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G,
Hillebrand MJ, Bartelink H, Verheij M. Phase I and pharmacokinetic study of combined
treatment with perifosine and radiation in patients with advanced solid tumours. Radiother
Oncol 2006;80(2):207-13
217. EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, Meijnen P,
Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A,
Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without
radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for
Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC
Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol
2006;20;24(21):3381-7
218. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price
A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C; on behalf of
the EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-
radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).
Eur J Cancer 2007;43(1):114-21
219. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer
JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late
cardiotoxicity after treatment for Hodgkin's lymphoma. Blood 2007;1;109(5):1878-86
220. Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, den Bogaert WV, Barillot,
Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Effect of age
and radiation dose on local control after breast conserving treatment: EORTC trial 22881-
10882. Radiother Oncol 2007;82(3):265-71
221. Musat E, Poortmans P, den Bogaert WV, Struikmans H, Fourquet A, Bartelink H, Kirkove C,
Budach V, Pierart M, Collette L. Quality assurance in breast cancer: EORTC experiences in
the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer 2007;43(4):718-
24
222. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van
Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J
Natl Cancer Inst 2007;7;99(5):365-75
223. Jansen EP, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J,
Valdes Olmos R, Bartelink H, Verheij M. Prospective study on late renal toxicity following
postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys
2007;1;67(3):781-5
224. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price
A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C; EORTC LCG
and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy patients
with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer
2007;43(1);114-21
225. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager
JJ, Hoogenraad WJ, Bing Oei S, Warlam-Rodenhuis CC, Pierart M, Collette L. Impact of a
Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early
Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-
Page 19 of 26
10882 Trial. J Clin Oncol 2007;1;25(22):3259-65
226. Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative
chemoradiotherapy in gastric cancer - a Phase I/II dose-finding study of radiotherapy with
dose escalation of cisplatin and capecitabine chemotherapy.Br J Cancer 2007;17;97(6):712-6
227. Bartelink H. Systemic adjuvant therapies and radiotherapy to the conserved breast: Strategies
revisited. Breast 2007;16(2):S84-8
228 Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH,
Stalpers LJ, Bartelink H, Begg AC.A Phase I-II Study of Postoperative Capecitabine-Based
Chemoradiotherapy in Gastric Cancer. Int J Radiat Oncol Biol Phys 2007;69(5):1424-8
229 Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A.
A Phase I-II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric
Cancer.Int J Radiat Oncol Biol Phys 2007;69(5):1424-8
230 Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Bartelink H, Van de Vijver MJ.Gene
expression profiling and histopathological characterization of triple negative/basal-like breast
carcinomas.Breast Cancer Res 2007;2;9(5):R65
231 Meijnen P, Bartelink H. Multifocal Ductal Carcinoma In Situ of the Breast: A Contraindication
for Breast-Conserving treatment? J Clin Oncol 2007;25(35):5548-9
232 H Bartelink, JC Horiot, P Poortmans, L Collette. In reply J Clin Oncol 2007:dec 20
233 Bartelink H. Systemic adjuvant therapies and radiotherapy to the conserved breast: strategies
revisited.Breast. 2007;16(2):S84-8 (review)
234 Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M.Postoperative
chemoradiotherapy in gastric cancer-a Phase I/II dose-finding study of radiotherapy with dose
escalation of cisplatin and capecitabine chemotherapy.Br J Cancer 2007;17;97(6):712-6
235 Vriens BH, Klaase JM, Schornagel JH, Bartelink H, Rutgers EJ.[A solitary sternal lesion found
by skeletal scintigraphy following treatment for breast carcinoma] Ned Tijdschr Geneeskunde
2007;1;151(35):1909-14
236 Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver
MJ.Gene expression profiling and histopathological characterization of triple-negative/basal-
like breast carcinomas.Breast Cancer Res 2007;9(5):R65
237 Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A,
Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M, Giordano SH, Muss H,
Aapro M; International Society of Geriatric Oncology.Management of breast cancer in elderly
individuals: recommendations of the International Society of Geriatric Oncology.Lancet Oncol
2007;8(12):1101-15(review)
238 Kreike B, Hart AA, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver
MJ. Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term
follow-up. Int J Radiat Oncol Biol Phys 2008;71(4):1014-21
239 Bartelink H, Begg AC.Prognostic and predictive markers in oncology. Introduction. Semin
Radiat Oncol 2008;18(2):73-4
240 Bartelink H.Progress in radiotherapy for early breast cancer. Ann Oncol 2008;19(5):117-21
241 Bartelink H, Arriagada R. Hypofractionation in radiotherapy for breast cancer.Lancet
2008;371(9618):1050-2
242 Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H,
Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox
B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane
M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema
T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A,
Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV,
Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M,
Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer
M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W,
Zaridze D, Zeng YX, Zhao P, Zheng T. Need for global action for cancer control. Ann Oncol
2008;19(9):1519-21
243 Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A,
Jager JJ, Hoogenraad W, Müller RP, Dubois JB, Bolla M, Van Der Hulst M, Wárlám-
Rodenhuis CC, Pierart M, Horiot JC; EORTC Radiation Oncology and Breast Cancer Groups.
The addition of a boost dose on the primary tumour bed after lumpectomy in breast
conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882
"boost versus no boost" trial. Cancer Radiother 2008;12(6-7):565-70
244 Bartelink H, Begg AC. Prognostic and predictive markers in oncology. Introduction. Semin
Radiat Oncol 2008;18:73-4
Page 20 of 26
245 Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert
W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DAL, Dubois JB,
Salamon E, Mirimanoff R, Bolla M, Van Der Hulst M, Rodenhuis CC, Bartelink H, EORTC
Radiation Oncology Group. Predictors of the risk of fibrosis at 10 years after breast conserving
therapy for early breast cancer - A study based on the EORTC trial 22881-10882 'boost
versus no boost'. Eur J Cancer 2008;44:2587-99
246 Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ.Clinical outcome after selective
treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol
2008;15(1):235-43
247 Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH,
Stalpers LJ, Bartelink H, Begg AC. Cisplatin-DNA adduct formation in patients treated with
cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer Chemother Pharmacol 2008;61(6):1075-81
248 Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH, de Jong D, Budde M,
Bartelink H, van Blitterswijk WJ, Verheij M.Alkylphospholipids inhibit capillary-like endothelial
tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Anticancer Drugs 2008;19(1):65-75
249 Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, Bartelink H, Rutgers
EJ, Gilhuijs KG. The impact of preoperative MRI on breast-conserving surgery of invasive
cancer: a comparative cohort study. Breast Cancer Res Treat 2009;116(1):161-9
250 Al Uwini S, Antonini N, Poortmans PM, Boersma L, Hurkmans C, Leer JW, Horiot JC,
Struikmans H, Bartelink H. The influence of the use of CT-planning on the irradiated boost
volume in breast conserving treatment. Radiother Oncol 2009;93(1):87-93
251 Atsma F, van der Schouw YT, Grobbee DE, Kors JA, Bartelink ML. Lifetime endogenous
estrogen exposure and electrocardiographic frontal T axis changes in postmenopausal
women. Maturitas 2009;63(4):347-51
252 De Bock GH, Putter H, Bonnema J, van der Hage JA, Bartelink H, van de Velde CJ. The
impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a
multistate model. Breast Cancer Res Treat 2009;117(2):401-8
253 Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB,
Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Wárlám-
Rodenhuis CC, Bartelink H. Impact of pathological characteristics on local relapse after
breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J
Clin Oncol 2009;27(30):4939-47
254 Poortmans PM, Collette L, Horiot JC, Van den Bogaert WF, Fourquet A, Kuten A, Noordijk
EM, Hoogenraad W, Mirimanoff RO, Pierart M, Van Limbergen E, Bartelink H. Impact of the
boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a
microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
Radiother Oncol 2009;90(1):80-5
255 Stroom J, Schlief A, Alderliesten T, Peterse H, Bartelink H, Gilhuijs K. Using histopathology
breast cancer data to reduce clinical target volume margins at radiotherapy. Int J Radiat Oncol
Biol Phys 2009;74(3):898-905
256 Verheij M, Bartelink H. Chemoradiotherapy. In: Schwab M (ed). Encyclopedia of Cancer, 2nd
ed.; part C. Springer,2009:625-628
257 Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, Bartelink H,
Rooswinkel R, Lafleur V, Verheij M. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2
family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.
Radiather Oncol 2009;4:47
258 Bartelink H, Meijnen P, Straver ME, Rutgers EJ. The EORTC experience: from DCIS to locally
advanced breast cancer. IN: Kuerer’s Breast Surgical Oncology. Chapter 45. Kuerer HM, Ed.
McGraw-Hill, New York 2010
259 Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W,
Fourquet A, Bartelink H, Ataman F, Gulyban A, Pierart M, Van Tienhoven G; EORTC
Radiation Oncology & Breast Cancer Groups. Toxicity at three years with and without
irradiation of the internal mammary and medial supraclaviculair lymph node chain in stage I to
III breast cancer (EORTC trial 22922/10925). Acta Oncol 2010;49(1):24-34
260 Borst GR, Sonke JJ, Hollander SD, Betgen A, Remeijer P, van Giersbergen A, Russell NS,
Elkhuizen PH, Bartelink H, van Vliet-Vroegindeweij C. Clinical results of Image-Guided Deep
Inspiration Breath Hold Breast Irradiation. Int J Radiat Oncol Biol Phys 2010;78(5):1345-51
261 Kreike B, Hart G, Bartelink H, van de Vijver MJ. Analysis of breast cancer related gene
expression using natural splines and the Cox proportional hazard model to identify prognostic
Page 21 of 26
associations. Breast Cancer Res Treat 2010;122(3):711-20
262 Schmitz AC, van den Bosch MA, Loo CE, Mali WP, Bartelink H, Gertenbach M, Holland R,
Peterse JL, Rutgers EJ, Gilhuijs KG. Precise correlation between MRI and histopathology –
exploring treatment margins for MRI-guided localized breast cancer therapy. Radiother Oncol
2010;97(2):225-32
263 Van Nes JGH, Putter H, van Hezewijk M, Hille ETM, Bartelink H, Collette L, van de Velde
CJH. Tailored follow-up for early breast cancer patients: a prognostic index that predicts
locoregional recurrence. Eur J of Surg Oncol 2010;36(7):617-24
264 Van der Hage JA, Mieog JSD, van de Velde CJH, Putter H, Bartelink H, van de Vijver MJ.
Impact of established prognostic factors and molecular subtype in very Young breast cancer
patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res
2011;24:13(3):R68
265 Van Werkhoven E, Hart G, Van Tinteren H, Elkhuizen P, Collette L, Poortmans P, Bartelink H.
Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC
22881-10882 boost versus no boost trial. Radiother Oncol 2011;100(1):101-7
266 Van der Leij F, Elkhuizen PH, Bartelink H, van de Vijver MJ. Predictive factors for local
recurrence in breast cancer.Semin Radiat Oncol 2012;22(2):100-7
267 Overgaard J, Bartelink H. Introduction: towards predicting outcome of radiotherapy-at last.
Semin Radiat Oncol 2012;22(2):87-90
268 Bartelink H, Bourgier C, Elkhuizen P. Has partial breast irradiation by IORT or brachytherapy
been prematurely introduced into the clinic? Radiother Oncol 2012;104(2):139-42
269 Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens
MH, Bogaerts J, Bartelink H. Breast conserving therapy versus mastectomy for stage I-II
breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol
2012;13(4):412-9
270 Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé
P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ. Search for
a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women. Clin
Cancer Res 2012;18(6):1704-15
271 Poortmans P, Aznar M, Bartelink H. Quality indicators for breast cancer: revisiting historical
evidence in the context of technology changes. Semin Radiat Oncol 2012;22(1):29-39
272 Chen W, Stroom J, Sonke JJ, Bartelink H, Schmitz AC, Gilhuijs KG. Impact of negative
margin width on local recurrence in breast conserving therapy. Radiother Oncol
2012;104(2):148-54
273 Immink JM, Putter H, Bartelink H, Cardoso JS, Cardoso MJ, van der Hulst-Vijgen MH,
Noordijk EM, Poortmans PM, Rodenhuis CC, Struikmans H. Long-term cosmetic changes
after breast-conserving treatment of patients with stage I-II breast cancer and included in the
EORTC ‘boost versus no boost’ trial. Ann Oncol 2012;23(10):2591-8
274 Schmitz A, Pengel K, Loo CE, van den Bosch MA, Wesseling J, Gertenbach M, Alderliesten
T, Mali WP, Rutgers EJ, Bartelink H, Gilhuijs KG. Pre-treatment imaging and pathology
characteristics of invasive breast cancers of limited extent: potential relevance for MRI-guided
localized therapy. Radiother Oncol 2012;104(1):11-8
275 Schwartz G, Reis-Fihlo J, Pusztai L, Fentiman IS, Holland R, Bartelink H, Rutgers EJ, Solin
LJ, Palazzo J; Consensus Committee. Adjuvant therapy in stage I carcinoma of the breast: the
influence of multigene analyses and molecular phenotyping. Cancer 2012;118(8):2031-8
276 Schwartz G, Bartelink H, Burstein H, Cady B Cataliotti L, Fentiman IS, Holland R, Hughes KS,
Masood S, McCormick B, Palazzo JA, Pressman PI, Reis-Filho J, Pusztai L, Rutgers EJ,
Seidman AD, Solin LJ, Sparano JA. Adjuvant therapy in stage I carcinoma of the breast: the
influence of multigene analyses and molecular phenotyping. Breast J 2012;18(4):303-11
277 Tanis E, van de Velde CJ, Bartelink H, van de Vijver MJ, Putter H, van der Hage JA.
Locoregional recurrence after breast-conserving therapy remains an independent prognostic
factor even after an event free interval of 10years in early stage breast cancer. Eur J Cancer
2012;48(12):1751-6
278 Betgen A, Alderliesten T, Sonke JJ, van Vliet-Vroegindeweij C, Bartelink H, Remeijer P.
Assessment of set-up variability during deep inspiration breath hold radiotherapy for breast
cancer patients by 3D-surface imaging. Radiother Oncol 2013;106(2):225-30
279 Mukesh MB, Harris E, Collette CE, Bartelink H, Wilkinson J, Evans PM, Graham P, Haviland
J, Poortmans P, Yarnold J, Jena R. Normal tissue complication probability (NTCP)
parameters for breast fibrosis: Pooled results from two randomised trials. Radiother Oncol
2013;108(2):293-98
280 Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT,
Page 22 of 26
Bartelink H, Duez N, Rutgers EJ, Bijker N. Donker M, Litière S, Werutsky G, Julien JP,
Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N.
Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15 years
recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase
III trial. J Clin Oncol 2013;31:4054-9
281 Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den
Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. Adaptive and
innovative radiation treatment for improving cancer treatment outcome (ARTFORCE); a
randomized controlled phase II trial for individualized treatment of head and neck cancer.
BMC Cancer 2013;22;13:84
282 Chen W, Gilhuijs K, Stroom J, Bartelink H, Sonke JJ. A simulation framework for modeling
tumor control probability in breast conserving therapy. Radiother Oncol. 2014 May;111(2):289-
95
283 Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B,
Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ. Gene
expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled
analysis. Breast Cancer Res Treat. 2014 Dec;148(3):599-613. doi: 10.1007/s10549-014-3188-
z. Epub 2014 Nov 21
284 Wilbers J, Hoebers FJ, Boogerd W, van Werkhoven ED, Nowee ME, Hart G, Bartelink H, van
Dijk EJ, Kappelle AC, Dorresteijn LD. Prospective Cohort Study of Carotid Intima-media
Thickness after Irradiation.J Stroke Cerebrovasc Dis. 2014 Oct 7
285 Wilbers J, Kappelle AC, Kessels RP, Steens SC, Meijer FJ, Kaanders JH, Haast RA,
Versteeg LE, Tuladhar AM, de Korte CL, Hansen HH, Hoebers FJ, Boogerd W, van
Werkhoven ED, Nowee ME, Hart G, Bartelink H, Dorresteijn LD, van Dijk EJ. Long term
cerebral and vascular complications after irradiation of the neck in head and neck cancer
patients: a prospective cohort study: study rationale and protocol. BMC Neurol. 2014 Jun 19
286 Harry Bartelink, Philippe Maingon, Philip Poortmans, Caroline Weltens, Alain Fourquet, Jos
Jager, Dominic Schinagl, Bing Oei, Carla Rodenhuis, Jean-Claude Horiot, Henk Struikmans,
Erik Van Limbergen, Youlia Kirova, Paula Elkhuizen, Rudolf Bongartz, Raymond Miralbell,
David Morgan,Jean-Bernard Dubois, Vincent Remouchamps, René-Olivier Mirimanoff,
Sandra Collette, Laurence Collette; Whole-breast irradiation with or without a boost for
patientstreated with breast-conserving surgery for early breast cancer: 20-year follow-up of a
randomised phase 3 trial. Lancet Oncology Dec. 1014
287 Harris E, Mukesh M, Jena R, Baker A, Bartelink H, Brooks C, Dean J, Donovan E, Collette S,
Eagle S, Fenwick J, Graham P, Haviland J, Kirby A, Mayles H. A multicentre observational
study evaluating image-guided radiotherapy for more accurate partial-breast intensity-
modulated radiotherapy: comparison with standard imaging technique. Efficacy Mech Eval
2014;1(3)
288 Harris EJ, Mukesh M, Jena R, Baker A, Bartelink H, Brooks C, Dean J, Donovan EM, Collette
S, Eagle S, Fenwick JD, Graham PH, Haviland JS, Kirby AM, Mayles H, Mitchell RA, Perry R,
Poortmans P, Poynter A, Shentall G, Titley J, Thompson A, Yarnold JR, Coles CE, Evans PM.
A multicentre observational study evaluating image-guided radiotherapy for more accurate
partial-breast intensity-modulated radiotherapy: comparison with standard imaging technique.
Southampton (UK): NIHR Journals Library; 2014 Nov
289 Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B,
Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ. Gene
expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled
analysis. Breast Cancer Res Treat. 2014 Dec;148(3):599-613
290 Wilbers J, Hoebers FJ, Boogerd W, van Werkhoven ED, Nowee ME, Hart G, Bartelink H, van
Dijk EJ, Kappelle AC, Dorresteijn LD. Prospective cohort study of carotid intima-media
thickness after irradiation. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2701-7
291 Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B,
Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R,
Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L;
European Organisation for Research and Treatment of Cancer Radiation Oncology and
Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated
with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised
phase 3 trial. Lancet Oncol. 2015 Jan;16(1):47-56
292 Chen W, Sonke JJ, Stroom J, Bartelink H, Verheij M, Gilhuijs K. The effect of age in breast
conserving therapy: a retrospective analysis on pathology and clinical outcome data.
Radiother Oncol. 2015 Mar;114(3):314-21
Page 23 of 26
293 van der Leij F, Bosma SC, van de Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, Bourgier C,
Garbay JR, Foukakis T, Lekberg T, van den Bongard DH, van Vliet-Vroegindeweij C, Bartelink
H, Rutgers EJ, Elkhuizen PH. First results of the preoperative accelerated partial breast
irradiation (PAPBI) trial. Radiother Oncol. 2015 Mar;114(3):322-7
294 Speers C, Zhao SG, Liu M, Bartelink H, Pierce LJ, Feng FY. Development and validation of a
novel radiosensitivity signature in human breast cancer. Clin Cancer Res. 2015 Apr 22
295 Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular
Irradiation in Breast Cancer. The New England journal of medicine 2015; 373(4): 317-27.
296 Bartelink H, Rutgers E, Wesseling J. Cavity Shave Margins in Breast Cancer.N Engl J Med.
2015 Nov 26;373(22):2186-8.
297 Poortmans PM, Struikmans H, Bartelink H. Regional Nodal Irradiation in Early-Stage Breast
Cancer. N Engl J Med. 2015 Nov 5;373(19):1879-80.
298 Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J, Tesselaar ME,
Vogel WV, Hoeben A, Zegers CM, Vugts DJ, van Dongen GA, Bartelink H, Mottaghy FM,
Hoebers F, Lambin P. Quantitative assessment of Zirconium-89 labeled cetuximab using
PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Oncotarget. 2017 Jan 17;8(3):3870-3880.
299 Bartelink H.The changing landscape in radiotherapy for breast cancer: Lessons from long term
follow-up in some European breast cancer trials. Radiother Oncol. 2016 Dec;121(3):348-356
300 Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink
H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY Maternal Embryonic Leucine
Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human
Breast Cancer. Clin Cancer Res. 2016 Dec 1;22(23):5864-5875.
301 Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D,
Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P,
Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G,
Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of
Cancer, Radiation Oncology and Breast Cancer Groups..Prognostic Factors for Local Control
in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A
Randomized Clinical Trial. JAMA Oncol. 2017 Jan 1;3(1):42-48.
302 van der Leij F, van Werkhoven E, Bosma S, Linn SC, Rutgers EJ, van de Vijver MJ, Bartelink H,
Elkhuizen PH, Scholten A. Low risk of recurrence in elderly patients treated with breast
conserving therapy in a single institute.Breast. 2016 Dec;30:19-25. doi:
10.1016/j.breast.2016.08.004.
303 Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH,
Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; Young
Boost Trial research group. Factors associated with patient-reported cosmetic outcome in the
Young Boost Breast Trial. Radiother Oncol. 2016 Jul;120(1):107-13.
304 Bosma SC, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, Rutgers EJ,
van de Vijver MJ, Elkhuizen PH. Very low local recurrence rates after breast-conserving
therapy: analysis of 8485 patients treated over a 28-year period. Breast Cancer Res Treat.
2016 Apr;156(2):391-400.
305 Bartelink H, Rutgers E, Wesseling J. Cavity Shave Margins in Breast Cancer.N Engl J Med.
2015 Nov 26;373(22):2186-7.
306 Poortmans PM, Struikmans H, Bartelink H.Regional Nodal Irradiation in Early-Stage Breast
Cancer. N Engl J Med. 2015 Nov 5;373(19):1879-80.
B) Books/chapters in books
1. Bartelink H. Lymph node metastases from squamous cell carcinomas of the head and neck region.
The role of radiotherapy. Thesis, University of Amsterdam, 1980
2. Bartelink H. Prognostic value of the regression rate of neck node metastases during radiotherapy.
Page 24 of 26
Clark RL, Cumley RW, Hickey RC (Eds). Yearbook of Cancer 1984. Chicago, Year Book Med
Publ; 30-31
3. Snow GB, Balm AJM, Arendse JW, Karim ABMF, Bartelink H, Van der Waal I, Tiwari RM.
Prognostic factors in neck node metastases. Larson (ed). Cancer in the neck: evaluation and
treatment. McMillan Company 1987; 53-63
4. Bartelink H, Begg AC, Dewit L, Stewart FA. Combined treatment with radiation and anti-cancer
drugs: experimental and clinical results Bleehen NM (ed). Radiobiology in Radiotherapy. Springer
Verslag 1988:177-199
5. Begg AC, Stewart FA, Dewit L, Bartelink H. Cisplatin-radiation interactions in tumours and normal
tissue Nicolini M (ed). Platinum and other metal coordination compounds in cancer chemotherapy
Boston Martinus Nijhoff 1988:74-80
6. Russell NS, Dewit L, Bartelink H. Clinical role of combined chemotherapy and radiotherapy.
Antitumor Drug-Radiation Interactions, 1989; chapter 14:247-264
7. Bartelink H, Borger JH. Breast conserving therapy: current and future role of interstitial boost
irradiation. Brachytherapy 2. Brachytherapy Working Conference, 5th International Selectron Users'
Meeting, The Hague 1988. Mould RF (ed). Nucletron Int. BV, Leersum; pp 497-502 (1989)
8. Begg AC, Stewart FA, Dewit L, Bartelink H. Interactions between cisplatin and radiation
experimental rodent tumors and normal tissues; Antitumor Drug-Radiation Interactions
1989;chapter 9:154-170
9. Van Dongen JA, Aaronson NK, Bartelink H. Selective Issues in the Evaluation of the Efficacy of
Breast-Conserving Therapy Breast Diseases, Kubli ea (eds). Springer-Verlag 1989:313-322
10. Snow GB, Balm AJM, Tiwari RM, Van der Waal I, Karim ABMF, Bartelink H. The role of surgery in
the prevention and management of metastic disease.Fee ea (eds). Head and Neck Cancer. 2.
American Society for Head and Neck Surgery Decker Inc 1990:252-257
11. Borger JH, Bartelink H. Iridium-192 afterloading for boosting the tumor bed. Interventional radiation
therapy: techniques – brachytherapy. (chapter 5.4:199-204) Edited by R. Sauer. Publisher
Springer-Verlag, Berlin Heidelberg, Germany 1991
12. Van Herk MB, Bijhold J, Blanckaert N, Crabeels D, Gilhuys KGA, Hoogervorst BR, Mijnheer BJ,
Mitine C, Moncuit D, Pinkster MBC, Pallotta S, Bartelink H. QUIRT: Real time imaging and quality
control in radiation therapy. Advances in medical informatics - Results of the AIM Exploratory
Action. J. Noothoven van van Goor, J.P. Christensen. IOS Press, Amsterdam, The Netherlands
1992:317-324
13. Jassem J, Dewit L, Keus R, Bartelink H. Concomitant chemotherapy and radiotherapy. In: Snow
GB, Clark JR, editors. Multimodality therapy for head and neck cancer. G Thieme Verlag, Stuttgart,
Germany / New York, USA 1992: 126-146
14. Horiot JC, Van der Schueren E, Johansson, Bernier J, Bartelink H. Quality assurance in
radiotherapy. In: Current Radiation Oncology. Edited by: J.S. Tobias and P.R.M. Thomas. Edward
Arnold, England 1994:365-381
15. Jassem J, Begg AC, Stewart FA, Bartelink H. Combined chemotherapy and radiotherapy. In:
Oxford Textbook of Oncology, Edited by: Peckham M, Pinedo HM, Veronesi U. Oxford University
Press 1995:811-823
16. Snow GB, Bartelink H. Management of cervical lymph nodes. In: Oxford Textbook of Oncology,
Edited by: Peckham M, Pinedo HM, Veronesi U. Oxford University Press 1995:1072-1082
17. De Ru VJ, Bartelink H. Radiotherapie, honderd jaar en verder. Het medisch jaar 1996. Edited by
Van Es JC, Keemn JN, De Leeuw PW, Verstraete M. Bohn Stafleu Von Loghum, Houten/Diegem,
The Netherlands
18. Annals of Oncology. Biliopancreatic Malignancy: From Gene to Cure Congress, February 4-6,
1999, Conference proceedings, volume 10, supplement 4. ISSN 0923-7534. Guest editor
19. B.R. Pieters, H. Bartelink. The role of hormonal treatment for locally advanced breast cancer.
Breast Cancer: Diagnosis and management, JM Dixon (Ed.), Elsevier Science B.V.
20. C.J.H. van de Velde, J.H. Schornagel, H. Bartelink. Mammatumoren. Oncologie, C.J.H. van de
Page 25 of 26
Velde, F.T. Bosman, D.J.Th. Wagener, Bohn Stafleum 2001
21. Stewart F, Bartelink H. Chapter: The combination of radiotherapy and chemotherapy. Book: Basic
Clinical Radiobiology; edited by Gordon Steel, 3rd edition. Distribution USA by Oxford University
Press Inc., New York 2002
22. van de Vijver M, van ’t Veer L, Vrieling C, Bartelink H. Chapter: Microarray analysis: An essential
tool for treatment tailoring in young patients with early breast cancer. Book: Progress in oncology
2003, editerd by Vincent T, DeVita Jr, Samuel Hellman, Steven A. Rosenberg. Jones and Barlett
Publishers, Sudbury, MA 01776, USA; 2003;ISBN 0-7637-2064-X
C) Articles in national medical journals
1. Bartelink H. Scintigraphy of the parasternal lymphnodes
Societas medica et chirurgica, Lunteren 1977:11-15
2. Bartelink H. Combination radiotherapy and chemotherapy: indications and complications.
Netherlands Oncology Society, Amsterdam 1978:9-13
3. Bartelink H, Somers R. Problemen bij de combinatie radiotherapie en chemotherapie.
Enkele bijwerkingen chemotherapie, preventie en behandeling. Samenvattingen van voordrachten
Vijftiende Oncologie Bijeenkomst Amsterdam 1978:9-13
4. Bartelink H. Developments in radiotherapy. Oncology for not-oncologic specialists, Leiden,
1979:159-164
5. Bartelink H, Battermann JJ, Hart AAM. Half-body irradiation. Gamma 1979;12; 250-251
6. Bartelink H, van Dongen JA. Mammasparende therapie bij het operabele mammacarcinoom
Gamma 1980;30:245-248
7. Bartelink H.
Ontwikkelingen in de radiotherapie: mamma-sparende behandeling bij het operabele
mammacarcinoom. Ned Tijdschr Geneesk 1980;124;41:1717-1718
8. Bartelink H, Somers R. De combinatie van radiotherapie en chemotherapie bij de behandeling van
maligne tumoren: indicaties en gevaren. Ned Tijdschr Geneesk 1980;124;15:564-568
9. Bartelink H. Ervaringen met mammasparende behandeling met behulp van iridium implantatie
(EORTC trial 10801) Veranderende opvattingen rond de behandeling van het primaire
mammacarcinoom. AvL, Wetensch Secr, Amsterdam 1980:20-22a
10. Bartelink H. Radiotherapie van het operabele mammacarcinoom. Ned Tijdschr Geneesk
1981;125;14:566-567
11. Bartelink H, Van Dongen JA. Mammasparende therapie bij operabel mammacarcinoom. Tijdschrift
voor Ziekenverpleging 1981;12:534-537
12. Bartelink H, Schouwenburg PF, Somers R. Een zwelling in de hals. Diagnostiek, behandeling en
resultaten bij patiënten met lymfekliermetastasen van hoofd-halstumoren. Ned Tijdschr Geneesk
1982;38;24:1587-1595
13. Hoefnagel CA, Bartelink H, Heidendal-Jeune M, Marcuse HR. Parasternale lymfoscintigrafie bij
patienten met een mammacarcinoom. Nucleair Geneeskundig Bulletin 1982;4:20-23
14. Bartelink H, Van Dongen JA, Van Dam FSAM, Van De Vijver M. Borstsparende behandeling bij het
operabele mammacarcinoom; eerste beoordeling van de resultaten. Ned Tijdschr Geneesk 1983
127(49):2223-2228
15. Heidendal-Jeune M, Schuster-Uitterhoeve L, Hoefnagel K, Bartelink H. Parasternale echografie:
waardevolle methode voor de stagering van mammacarcinoom? Ned Tijdschr Geneesk
1983;127:1703-1704
16. Bartelink H, Bergman RB, Van Dongen JA. Veranderende opvattingen ten aanzien van de
locoregionale behandeling van het mammacarcinoom. Mammacarcinoom: nieuwe aspekten bij
diagnostiek en behandeling. Uitgeverij Stafleu, Alphen a/d Rijn/Brussel 1984
17. Van Dongen JA, Bartelink H. Mammasparende therapie bij het operabele mammacarcinoom. Het
Medisch Jaar 1984. Bohn, Scheltema & Holkema, Utrecht/Antwerpen 1984:272-297
18. Keus RB, Bartelink H, Albus-Lutter ChE, Gortzak E. De mogelijkheden van radiotherapie bij de
Page 26 of 26
behandeling van desmoid tumoren. Ned Tijdschr Geneesk 1985;129:1585-1588
19. Van Dongen JA, Bartelink H. Dilemma's bij de indicatie voor radiotherapie na borstamputatie. Ned
Tijdschr Geneesk 1985;129:1861-1863
20. Van Dongen JA, Bartelink H. De locoregionale therapie van het mammacarcinoom; verschuivingen
naar mammasparende therapie. Practitioner 2 (Ned.ed.) 1985:1001-1008
21. Van Dongen JA, Bartelink H, Van de Sluis T, Veen R, Van Uden M, Modder C. Mammasparende
therapie bij operabel mammacarcinoom: indicatiestelling, resultaten, problemen. Ned Tijdschr
Geneesk 1985;129:2188-2189
22. Bartelink H, Van Dongen JA, Peterse JL. Borstsparende behandelingen bij patienten met
mammacarcinoom stadium I en II. Ned Tijdschr Geneesk 1988;29:1326-1330
23. Van Bunningen BNFM, Dewit L, Bartelink H. De ziekte van Hodgkin bij kinderen;
behandelingsresultaten met of zonder radiotherapie. Ned Tijdschr Geneesk 1986;130:928-929
24. Bartelink H. Experimentele en klinische radiobiologie. Van Radicaal tot Primaat (Lustrumboek
Ned.Ver.Radiobiol., 30 jaar. Radiobiologie in Nederland) 1989:173-178
25. Van Dongen JA, Bartelink H, Peterse JL. Het plaatselijk recidief na borstsparende therapie van
mammacarcinoom. Ned Tijdsch Geneeskd 1989;133:2595-2598
26. Bruning PF, Bartelink H, Van Dongen JA, Peterse JL. Adjuvante behandeling van het
mammacarcinoom. Ned Tijdsch Geneeskd 1993;137:2364-2570
27. Haas RLM, Bartelink H. Botpijnen bij kankerpatiënten met kanker berusten niet altijd op
botmetastasen. Ned Tijdschr Geneeskd 1995;139;7:305-308
28. Inwendige radiotherapie bij prostaatcarcinoom; tegenvallende lange-termijnresultaten van
retropubische Jodium-125-implantatie. Roeleveld TA, Horenblas S, Moonen LMF, te Velde A,
Meinhardt W, Bartelink H. Ned Tijdschr Geneeskd 1996;140;37:1855-1859
29. Goede resultaten van blaassparende behandeling bij slecht gedifferentieerde en invasieve
blaascarcinomen met behulp van essentiële Iridium-192-radiotherapie. Ned Tijdschr Geneeskd
1996;140:1406-1410
30. Jansen EPM, Valdés Olmos RA, Dewit LGH, Hamburger HL, Bartelink H, Hoefnagel CA. Residual
pituitary adenoma visualized by functional 99mTc-HMPAO SPECT. Tijdschr Nucl Geneeskd
1999;21; 2:76-79
31. Bartelink H. Commentaar: Totale mesorectale excisie en voorafgaande radiotherapie bij patiënten
met rectumcarcinoom: goede voorlopige behandelresultaten. Ned Tijdschr Geneesk 2001;145; 47:
2259-2260
32. Bartelink H, Poortmans PhMP, Struikmans H, Borger JH, Jager JJ, Hoogenraad WJ, Van den
Bogaert W, et al. Minder lokale recidieven van borstkanker door extra lokale bestralingsdosis na
mammasparende chirurgie; 5-jaarsresultaten van een klinische trial. Ned Tijdschr Geneesk
2002;146:416-423
33. Bartelink H, Schellens JHM, Verheij M. De gecombineerde toepassing van radiotherapie en
chemotherapie bij de behandeling van solide maligne tumoren. Ned Tijdschr Geneesk 2002;146;
504-508
34 Scholten AN, Rutgers EJ, Bartelink H Radiotherapy and breast conserving therapy: past,present
and future]. Ned Tijdschr Geneeskd. 2015;159:A9289.
